35 results on '"Egocheaga, I"'
Search Results
2. Impacto de dapagliflozina en los factores de riesgo cardiovascular. Más allá del control de la glucemia
- Author
-
Pallarés, V., Escobar, C., Egocheaga, I., and Obaya, J.C.
- Published
- 2021
- Full Text
- View/download PDF
3. Dapagliflozina en la prevención y tratamiento de la insuficiencia cardiaca
- Author
-
Egocheaga, I., Escobar, C., Pallarés, V., and Obaya, J.C.
- Published
- 2021
- Full Text
- View/download PDF
4. Clinical characteristics and management of patients with atrial fibrillation treated with direct oral anticoagulants according to blood pressure control
- Author
-
de la Figuera, M., Cinza, S., Egocheaga, I., Marín, N., and Prieto, M.A.
- Published
- 2018
- Full Text
- View/download PDF
5. Diferencias en el manejo de los pacientes con fibrilación auricular según inicie el tratamiento con anticoagulantes orales de acción directa el médico de atención primaria o el especialista. Estudios SILVER-AP y BRONCE-AP
- Author
-
de la Figuera, M., Prieto, M.A., Marín, N., Egocheaga, I., and Cinza, S.
- Published
- 2018
- Full Text
- View/download PDF
6. EE498 Cost of Follow-Up After an Ischemic Cerebrovascular Event in Patients With Atherosclerotic Cardiovascular Disease in Spain: Results from the Reality Study
- Author
-
Castellanos, M, primary, Games, JM, additional, Mostaza, JM, additional, Egocheaga, I, additional, Gomez Cerezo, J, additional, Campuzano, R, additional, Pallares, V, additional, Barrios, V, additional, Morant Talamante, N, additional, Sicras-Mainar, A, additional, Pérez Román, I, additional, Rodriguez Barrios, JM, additional, Parrondo García, FJ, additional, and Martinez, I, additional
- Published
- 2022
- Full Text
- View/download PDF
7. EE636 Cost of Follow-Up After a Peripheral Arterial Event in Patients With Atherosclerotic Cardiovascular Disease in Spain: Results From the Reality Study
- Author
-
Egocheaga, I, primary, Games, JM, additional, Barrios, V, additional, Martinez, I, additional, Mostaza, JM, additional, Gomez Cerezo, J, additional, Castellanos, M, additional, Campuzano, R, additional, Morant Talamante, N, additional, Rodriguez Barrios, JM, additional, Sicras-Mainar, A, additional, Pérez Román, I, additional, Parrondo García, FJ, additional, and Pallares, V, additional
- Published
- 2022
- Full Text
- View/download PDF
8. EE637 Cost of Follow-Up in Patients With Heterozygous Familial Hypercholesterolemia in Spain: Results From the Reality Study
- Author
-
Mostaza, JM, primary, Martinez, I, additional, Games, JM, additional, Pallares, V, additional, Campuzano, R, additional, Egocheaga, I, additional, Castellanos, M, additional, Gomez Cerezo, J, additional, Morant Talamante, N, additional, Rodriguez Barrios, JM, additional, Sicras-Mainar, A, additional, Pérez Román, I, additional, Parrondo García, FJ, additional, and Barrios, V, additional
- Published
- 2022
- Full Text
- View/download PDF
9. EE84 Cost of Follow-Up After an Ischemic Heart Disease Event in Patients With Atherosclerotic Cardiovascular Disease in Spain: Results From the Reality Study
- Author
-
Martinez, I, primary, Barrios, V, additional, Pallares, V, additional, Campuzano, R, additional, Castellanos, M, additional, Gomez Cerezo, J, additional, Egocheaga, I, additional, Games, JM, additional, Morant Talamante, N, additional, Rodriguez Barrios, JM, additional, Sicras-Mainar, A, additional, Pérez Román, I, additional, Parrondo García, FJ, additional, and Mostaza, JM, additional
- Published
- 2022
- Full Text
- View/download PDF
10. Preliminary results from REALITY: a nation-wide study of a database with 1.8 million real-life patients to study atherosclerotic cardiovascular disease and familial hypercholesterolemia in Spain
- Author
-
Campuzano, R, primary, Barrios, V, additional, Mostaza, J M, additional, Egocheaga, I, additional, Perez Roman, I, additional, Martinez Lopez, A, additional, Sicras-Mainar, A, additional, Morant Talamante, N, additional, Parrondo, J, additional, Gomez Cerezo, J F, additional, Pallares, V, additional, Martinez Lopez, I, additional, Castellanos, M, additional, and Gamez, J M, additional
- Published
- 2022
- Full Text
- View/download PDF
11. The REALITY project: analysis of a national database with 1.8 million real-life patients to study atherosclerotic cardiovascular disease and familial hypercholesterolemia in Spain
- Author
-
Barrios, V, primary, Campuzano, R, additional, Egocheaga, I, additional, Martinez Lopez, I, additional, Castellanos, M, additional, Perez Roman, I, additional, Martinez Lopez, A, additional, Sicras-Mainar, A, additional, Morant Talamante, N, additional, Parrondo, J, additional, Mostaza, J M, additional, Gomez Cerezo, J F, additional, Gamez, J M, additional, and Pallares, V, additional
- Published
- 2022
- Full Text
- View/download PDF
12. Volume Overload, Atrial Natriuretic Peptide, and Left Ventricular Hypertrophy
- Author
-
Luque Otero, M., Martell, N., Aubele, A. L., Rodrigo, J. L., Herrero, M., Moya, J., Egocheaga, I., Fernández-Cruz, A., Pinilla, C. Fernandez, Zanchetti, Alberto, editor, Devereux, Richard B., editor, Hansson, Lennart, editor, and Gorini, Sergio, editor
- Published
- 1997
- Full Text
- View/download PDF
13. Hipertrofia ventricular izquierda por electrocardiograma o ecocardiograma y complicaciones cardiovasculares en hipertensos tratados de la Comunidad Autónoma de Madrid. Estudio MAVI-HTA
- Author
-
Luque, M., Galgo, A., Abad, E., Egocheaga, I., de la Cruz, J.J., Cea-Calvo, L., and Zamorano, J.L.
- Published
- 2008
- Full Text
- View/download PDF
14. Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology
- Author
-
Escobar C, Anguita M, Arrarte V, Barrios V, Cequier A, Cosin-Sales J, Egocheaga I, de Sa E, Masana L, Pallares V, de Isla L, Pinto X, Juanatey J, and Zamorano J
- Subjects
Ischemic heart disease ,Secondary prevention ,LDL-cholesterol ,Lipid-lowering therapy - Abstract
The current control of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease is very low and this is associated with an increase of cardiovascular outcomes. In addition, the latter this happens, the risk will be greater. This is mainly due to an insufficient use of the lipid-lowering therapy currently available. In fact, with current treatments (statins, ezetimibe and PCSK9 inhibitors), the majority of patients in secondary prevention should achieve low-density lipoprotein cholesterol goals. For these reasons, in this manuscript promoted by the Spanish Society of Cardiology we propose three simple and feasible decision-making algorithms that include the majority of clinical scenarios among patients with ischemic heart disease, with the double aim of attaining therapeutic goals in the majority of patients as soon as possible; in secondary prevention the magnitude of the benefit is risk- and time-dependent. (C) 2019 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
- Published
- 2020
15. Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish Society of Cardiology
- Author
-
Barrios V, Cosin-Sales J, Bravo M, Escobar C, Gamez J, Huelmos A, Cortes C, Egocheaga I, Garcia-Pinilla J, Jimenez-Candil J, Lopez-de-Sa E, Llergo J, Obaya J, Pallares-Carratala V, Sanmartin M, Vidal-Perez R, and Cequier A
- Subjects
Ischemic heart disease ,Heart failure ,Arrhythmias ,Telemedicine - Abstract
The coronavirus disease 2019 (COVID-19) pandemic has changed how we view our consultations. To reduce the risk of spread in the most vulnerable patients (those with heart disease) and health personnel, most face-to-face consultations have been replaced by telemedicine consultations. Although this change has been rapidly introduced, it will most likely become a permanent feature of clinical practice. Nevertheless, there remain serious doubts about organizational and legal issues, as well as the possibilities for improvement etc. In this consensus document of the Spanish Society of Cardiology, we attempt to provide some keys to improve the quality of care in this new way of working, reviewing the most frequent heart diseases attended in the cardiology outpatient clinic and proposing some minimal conditions for this health care process. These heart diseases are ischemic heart disease, heart failure, and arrhythmias. In these 3 scenarios, we attempt to clarify the basic issues that must be checked during the telephone interview, describe the patients who should attend in person, and identify the criteria to refer patients for follow-up in primary care. This document also describes some improvements that can be introduced in telemedicine consultations to improve patient care. (C) 2020 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
- Published
- 2020
16. P3815Cost and burden of poor control of the level of anticoagulation in patients with non-valvular atrial fibrillation treated with vitamin K antagonist in the Spanish National Health Service
- Author
-
Burgos-Pol, R, primary, Barrios, V, additional, Cinza-Sanjurjo, S, additional, Gavin, O, additional, Egocheaga, I, additional, Soto, J, additional, Polanco, C, additional, Suarez, J, additional, and Casado, M A, additional
- Published
- 2019
- Full Text
- View/download PDF
17. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2
- Author
-
Huisman, M. V., Rothman, K. J., Paquette, M., Teutsch, C., Diener, H. -C., Dubner, S. J., Halperin, J. L., C. S., Ma, Zint, K., Elsaesser, A., Bartels, D. B., Lip, G. Y. H., Abban, D., Abdul, N., Abelson, M., Ackermann, A., Adams, F., Adams, L., Adragao, P., Ageno, W., Aggarwal, R., Agosti, S., Marin, J. A., Aguilar, F., Aguilar Linares, J. A., Aguinaga, L., Ahmad, Z., Ainsworth, P., Al Ghalayini, K., Al Ismail, S., Alasfar, A., Alawwa, A., Al-Dallow, R., Alderson, L., Alexopoulos, D., Ali, A., Ali, M., Aliyar, P., Al-Joundi, T., Al Mahameed, S., Almassi, H., Almuti, K., Al-Obaidi, M., Alshehri, M., Altmann, U., Alves, A. R., Al-Zoebi, A., Amara, W., Amelot, M., Amjadi, N., Ammirati, F., Andrawis, N., Angoulvant, D., Annoni, G., Ansalone, G., Antonescu, S. A., Ariani, M., Arias, J. C., Armero, S., Arora, R., Arora, C., Ashcraft, W., Aslam, M. S., Astesiano, A., Audouin, P., Augenbraun, C., Aydin, S., Azar, R., Azim, A., Aziz, S., Backes, L. M., Baig, M., Bains, S., Bakbak, A., Baker, S., Bakhtiar, K., Bala, R., Banayan, J., Bandh, S., Bando, S., Banerjee, S., Bank, A., Barbarash, O., Baron, G., Barr, C., Barrera, C., Barton, J., Kes, V. B., Baula, G., Bayeh, H., Bazargani, N., Behrens, S., Bell, A., Benezet-Mazuecos, J., Benhalima, B., Berdague, P., Berg van den, B. J., Bergen van, P. F. M. M., Berngard, E., Bernstein, R., Berrospi, P., Berti, S., Bertomeu, V., Berz, A., Bettencourt, P., Betzu, R., Beyer-Westendorf, J., Bhagwat, R., Black, T., Blanco Ibaceta, J. H., Bloom, S., Blumberg, E., Bo, M., Bockisch, V., Bohmer, E., Bongiorni, M. G., Boriani, G., Bosch, R., Boswijk, D. J., Bott, J., Bottacchi, E., Kalan, M. B., Brandes, A., Bratland, B., Brautigam, D., Breton, N., Brouwers, P. J. A. M., Browne, K., Bruguera, J., Brunehaut, M., Brunschwig, C., Buathier, H., Buhl, A., Bullinga, J., Butcher, K., Cabrera Honorio, J. W., Caccavo, A., Cadinot, D., Cai, S., Calvi, V., Camm, J., Candeias, R., Capo, J., Capucci, A., Cardoso, J. N., Duarte Vera, Y. C., Carlson, B., Carvalho, P., Cary, S., Casanova, R., Casu, G., Cattan, S., Cavallini, C., Cayla, G., Cha, T. J., Cha, K. S., Chaaban, S., Chae, J. K., Challappa, K., Chand, S., Chandrashekar, H., Chang, M., Charbel, P., Chartier, L., Chatterjee, K., Cheema, A., Chen, S. -A., Chevallereau, P., Chiang, F. -T., Chiarella, F., Chih-Chan, L., Cho, Y. K., Choi, D. J., Chouinard, G., Danny, Chow, H. F., Chrysos, D., Chumakova, G., Jose Roberto Chuquiure Valenzuela, E. J., Cieza-Lara, T., Nica, V. C., Ciobotaru, V., Cislowski, D., Citerne, O., Claus, M., Clay, A., Clifford, P., Cohen, S., Cohen, A., Colivicchi, F., Collins, R., Compton, S., Connors, S., Conti, A., Buenostro, G. C., Coodley, G., Cooper, M., Corbett, L., Corey, O., Coronel, J., Corrigan, J., Cotrina Pereyra, R. Y., Cottin, Y., Coutu, B., Cracan, A., Crean, P., Crenshaw, J., Crijns, H. J. G. M., Crump, C., Cucher, F., Cudmore, D., Cui, L., Culp, J., Darius, H., Dary, P., Dascotte, O., Dauber, I., Davee, T., Davies, R., Davis, G., Davy, J. -M., Dayer, M., De La Briolle, A., de Mora, M., De Teresa, E., De Wolf, L., Decoulx, E., Deepak, S., Defaye, P., Del-Carpio Munoz, F., Brkljacic, D. D., Deluche, L., Destrac, S., Deumite, N. J., Di Legge, S., Dibon, O., Diemberger, I., Dillinger, J., Dionisio, P., Naydenov, S., Dotani, I., Dotcheva, E., D'Souza, A., Dubrey, S., Ducrocq, X., Dupljakov, D., Duthinh, V., Dutra, O. P., Dutta, D., Duvilla, N., Dy, J., Dziewas, R., Eaton, C., Eaves, W., Ebinger, M., Eck van, J. W. M., Edwards, T., Egocheaga, I., Ehrlich, C., Eisenberg, S., El Hallak, A., El Jabali, A., El Mahmoud, R., El Shahawy, M., Eldadah, Z., Elghelbazouri, F., Elhag, O., El-Hamdani, M., Elias, D., Ellery, A., El-Sayed, H., Elvan, A., Erickson, B., Espaliat, E., Essandoh, L., Everington, T., Evonich, R., Ezhov, A., Facila, L., Farsad, R., Fayard, M., Fedele, F., Gomes Ferreira, L. G., Ferreira, D., Santos, J. F., Ferrier, A., Finsen, A., First, B., Fisher, R., Floyd, J., Folk, T., Fonseca, C., Fonseca, L., Forman, S., Forsgren, M., Foster, M., Foster, N., Frais, M., Frandsen, B., Frappe, T., Freixa, R., French, W., Freydlin, M., Frickel, S., Fruntelata, A. G., Fujii, S., Fujino, Y., Fukunaga, H., Furukawa, Y., Gabelmann, M., Gabris, M., Gadsboll, N., Galin, P., Galinier, M., Ganim, R., Garcia, R., Quintana, A. G., Gartenlaub, O., Genz, C., Georger, F., Georges, J. -L., Georgeson, S., Ghanbasha, A., Giedrimas, E., Gierba, M., Gillespie, E., Giniger, A., Gkotsis, A., Gmehling, J., Gniot, J., Goethals, P., Goldberg, R., Goldmann, B., Goldscher, D., Golitsyn, S., Gomez Lopez, E. A., Gomez Mesa, J. E., Gonzalez, E., Cocina, E. G., Juanatey, C. G., Gorbunov, V., Gordon, B., Gorka, H., Gornick, C., Gorog, D., Goss, F., Gotte, A., Goube, P., Goudevenos, I., Goulden, D., Graham, B., Grande, A., Greco, C., Green, M., Greer, G., Gremmler, U., Grena, P., Grinshstein, Y., Grond, M., Gronda, E., Grondin, F., Gronefeld, G., Groot de, J. R., Guardigli, G., Guarnieri, T., Caiedo, C. G., Guignier, A., Gulizia, M., Gumbley, M., Gupta, D., Hack, T., Haerer, W., Hakas, J., Hall, C., Hampsey, J., Hananis, G., Hanbali, B., Handel, F., Hargrove, J., Hargroves, D., Harris, K., Hartley, D., Haruna, T., Hata, Y., Hayek, E., Healey, J., Hearne, S., Heggelund, G., Hemels, M. E. W., Hemery, Y., Henein, S., Henz, B., Her, S. -H., Hermany, P., Hernandes, M. E., Higashino, Y., Hill, M., Hisadome, T., Hishida, E., Hitchcock, J., Hoffer, E., Hoghton, M., Holmes, C., Hong, S. K., Houppe Nousse, M. -P., Howard, V., Hsu, L. F., Huang, C. -H., Huckins, D., Huehnergarth, K., Huizenga, A., Huntley, R., Hussein, G., Hwang, G. -S., Igbokidi, O., Iglesias, I., Ikpoh, M., Imberti, D., Ince, H., Indolfi, C., Ionova, T., Ip, J., Irles, D., Iseki, H., Ismail, Y., Israel, N., Isserman, S., Iteld, B., Ivanchura, G., Iyer, R., Iyer, V., Iza Villanueva, R. O., Jackson-Voyzey, E., Jaffrani, N., Jager, F., Jain, M., James, M., Jamon, Y., Jang, S. W., Pereira Jardim, C. A., Jarmukli, N., Jeanfreau, R., Jenkins, R., Jiang, X., Jiang, H., Jiang, T., Jiang, N., Jimenez, J., Jobe, R., Joffe, I., Johansson, B., Jones, N., Moura Jorge, J. C., Jouve, B., Jundi, M., Jung, W., Jung, B. C., Jung, K. T., Kabbani, S., Kabour, A., Kafkala, C., Kajiwara, K., Kalinina, L., Kampus, P., Kanda, J., Kapadia, S., Karim, A., Karolyi, L., Kashou, H., Kastrup, A., Katsivas, A., Kaufman, E., Kawai, K., Kawajiri, K., Kazmierski, J., Keeling, P., Kerfes, G. A., Kerr Saraiva, J. F., Ketova, G., Khaira, A., Khalid, M., Khludeeva, E., Khripun, A., Kim, D. I., Kim, D. K., Kim, N. H., Kim, K. S., Kim, Y. -H., Kim, J. B., Kim, J. S., Kinova, E., Klein, A., Kleinschnitz, C., Kmetzo, J., Kneller, G. L., Knezevic, A., Koch, S., Koenig, K., Angela Koh, S. M., Kohrmann, M., Koons, J., Korabathina, R., Korennova, O., Koschutnik, M., Kosinski, E., Kovacic, D., Kowalczyk, J., Koziolova, N., Kragten, J. A., Krause, L. U., Kreidieh, I., Krenning, B. J., Krishnaswamy, K., Krysiak, W., Kuck, K. -H., Kumar, S., Kumler, T., Kuniss, M., Kuo, J. -Y., Kuppers, A., Kurrelmeyer, K., Kwan, T., Kyo, E., Labovitz, A., Lacroix, A., Lam, A., Lanas Zanetti, F. T., Landau, C., Landini, G., Lang, W., Larsen, T. B., Laske, V., Lavandier, K., Law, N., Lee, M. H., Lee, D., Leitao, A., Lejay, D., Lelonek, M., Lenarczyk, R., Leprince, P., Lequeux, B., Leschke, M., Ley, N., Li, Z., Li, Y., Li, X., Li, W., Liang, J., Lieber, I., Lillestol, M., Limon Rodriguez, R. H., Lin, H., Lip, G., Litchfield, J., Liu, Z., Liu, X., Liu, Y., Liu, F., Liu, W., Llamas Esperon, G. A., Llisterri, J. L., Lo, T., Lo, E., Lobos, J. M., Lodde, B. -P., Loiselet, P., Lopez-Sendon, J., Lorga Filho, A. M., Lori, I., Luo, M., Lupovitch, S., Lyrer, P., Zuhairy, H. M., Ma, C., Ma, G., Ma, H., Madariaga, I., Maeno, K., Magnin, D., Mahmood, S., Mahood, K., Maid, G., Mainigi, S., Makaritsis, K., Maldonado Villalon, J. A., Malhotra, R., Malik, A., Mallecourt, C., Mallik, R., Manning, R., Manolis, A., Mantas, I., Manzur Jattin, F. G., Marcionni, N., Marin, F., Santana, A. M., Martinez, J., Martinez, L., Maskova, P., Hernandez, N. M., Matskeplishvili, S., Matsuda, K., Mavri, A., May, E., Mayer, N., Mazon, P., Mcclure, J., Mccormack, T., Mcgarity, W., Mcguire, M., Mcintyre, H., Mclaughlin, P., Mclaurin, B., Medina Palomino, F. A., Mehta, P., Mehzad, R., Meinel, A., Melandri, F., Mena, A., Meno, H., Menzies, D., Metcalf, K., Meyer, B., Miarka, J., Mibach, F., Michalski, D., Michel, P., Chreih, R. M., Mikdadi, G., Mikhail, M., Mikus, M., Milicic, D., Militaru, C., Miller, G., Milonas, C., Minescu, B., Mintale, I., Miralles, A., Mirault, T., Mistry, D., Mitchell, G., Miu, N. V., Miyamoto, N., Moccetti, T., Mohammed, A., Nor, A. M., Molina de Salazar, D. I., Molon, G., Molony, D., Mondillo, S., Mont, L., Moodley, R., Moore, R., Ribeiro Moreira, D. A., Mori, K., Moriarty, A., Morka, J., Moschos, N., Mota Gomes, M. A., Mousallem, N., Moya, A., Mugge, A., Mulhearn, T., Muller, J. -J., Muresan, C. M., Muse, D., Musial, W., Musumeci, F., Nadar, V., Nageh, T., Nair, P., Nakagawa, H., Nakamura, Y., Nakayama, T., Nam, K. -B., Napalkov, D., Natarajan, I., Nayak, H., Nechvatal, L., Neiman, J., Nerheim, P., Neuenschwander, F. C., Nishida, K., Nizov, A., Novikova, T., Novo, S., Nowalany-Kozielska, E., Nsah, E., Nunez Fragoso, J. C., Nyvad, O., de Los Rios Ibarra, M. O., O'Donnell, M., O'Donnell, P., D. J., Oh, Y. S., Oh, Daniel Oh, C. T., O'Hara, G., Oikonomou, K., Olalla, J. J., Olivari, Z., Oliver, R., Olympios, C., Osborne, J., Osca, J., Osman, R., Osunkoya, A., Padanilam, B., Panchenko, E., Pandey, A. S., Vicenzo de Paola, A. A., Paraschos, A., Pardell, H., Park, H. W., Park, J. S., Parkash, R., Parker, I., Parrens, E., Parris, R., Passamonti, E., Patel, J., Patel, R., Pentz, W. H., Persic, V., Perticone, F., Peters, P., Petkar, S., Pezo, L. F., Pham, D., Cao Phai, G. P., Phlaum, S., Pineau, J., Pineda-Velez, A., Pini, R., Pinter, A., Pinto, F., Pirelli, S., Pivac, N., Pizzini, A. M., Pocanic, D., Calin Podoleanu, C. G., Polanczyk, C. A., Polasek, P., Poljakovic, Z., Pollock, S., Polo, J., Poock, J., Poppert, H., Porro, Y., Pose, A., Poulain, F., Poulard, J. -E., Pouzar, J., Povolny, P., Pozzer, D., Pras, A., Prasad, N., Prevot, S., Protasov, K., Prunier, L., Puleo, J., Pye, M., Qaddoura, F., Quedillac, J. -M., Raev, D., Rahimi, S., Raisaro, A., Rama, B., Ranadive, N., Randall, K., Ranjith, N., Raposo, N., Rashid, H., Raters, C., Rauch-Kroehnert, U., Rebane, T., Regner, S., Renzi, M., Reyes Rocha, M. A., Reza, S., Ria, L., Richter, D., Rickli, H., Rickner, K., Rieker, W., Rigo, F., Ripoll, T., Fonteles Ritt, L. E., Roberts, D., Pascual, C. R., Briones, I. R., Reyes, H. R., Roelke, M., Roman, M., Romeo, F., Ronner, E., Ronziere, T., Rooyer, F. A., Rosenbaum, D., Roth, S., Rozkova, N., Rubacek, M., Rubalcava, F., Rubanenko, O., Rubin, A., Borret, M. R., Rybak, K., Sabbour, H., Morales, O. S., Sakai, T., Salacata, A., Salecker, I., Salem, A., Salfity, M., Salguero, R., Salvioni, A., Samson, M., Sanchez, G., Sandesara, C., Saporito, W. F., Sasaoka, T., Sattar, P., Savard, D., Scala, P. -J., Scemama, J., Schaupp, T., Schellinger, P., Scherr, C., Schmitz, K. -H., Schmitz, B., Schmitz, L., Schnitzler, R., Schnupp, S., Schoeniger, P., Schon, N., Schuster, S., Schwimmbeck, P., Seamark, C., Seebass, R., Seidl, K. -H., Seidman, B., Sek, J., Sekaran, L., Seko, Y., Sepulveda Varela, P. A., Sevilla, B., Shah, V., Shah, A., Shah, N., Shanes, J., Sharareh, A., Sharma, V. K., Shaw, L., Shimizu, Y., Shimomura, H., Shin, D. G., Shin, E. -S., Shite, J., Shoukfeh, M., Shoultz, C., Silver, F., Sime, I., Simmers, T. A., Singal, D., Singh, N., Siostrzonek, P., Sirajuddin, M., Skeppholm, M., Smadja, D., Smith, R., Smith, D., Soda, H., Sofley, C. W., Sokal, A., Sotolongo, R., de Souza, O. F., Sparby, J. A., Spinar, J., Sprigings, D., Spyropoulos, A., Stakos, D., Steinberg, A., Steinwender, C., Stergiou, G., Stites, H. W., Stoikov, A., Strasser, R., Streb, W., Styliadis, I., Su, G., Su, X., Suarez, R. M., Sudnik, W., Sueyoshi, A., Sukles, K., Sun, L., Suneja, R., Svensson, P., Ziekenhuis, A., Szavits-Nossan, J., Taggeselle, J., Takagi, Y., Takhar, A., Tallet, J., Tamm, A., Tanaka, S., Tanaka, K., Tang, A., Tang, S., Tassinari, T., Tayama, S., Tayebjee, M., Tebbe, U., Teixeira, J., Tesloianu, D. N., Tessier, P., The, S. H. K., Thevenin, J., Thomas, H., Timsit, S., Topkis, R., Torosoff, M., Touze, E., Traissac, T., Trendafilova, E., Troyan, B., Tsai, W. K., Tse, H. F., Tsutsui, H., Tsutsui, T., Tuininga, Y. S., Turakhia, M., Turk, S., Turner, W., Tveit, A., Twiddy, S., Tytus, R., Ukrainski, G., Valdovinos Chavez, S. B., Van De Graaff, E., Vanacker, P., Vardas, P., Vargas, M., Vassilikos, V., Vazquez, J., Venkataraman, A., Verdecchia, P., Vester, E. G., Vial, H., Vinereanu, D., Vlastaris, A., Vogel, C., vom Dahl, J., von Mering, M., Vora, K., Wakefield, P., Walia, J., Walter, T., Wang, M., Wang, N., Wang, F., Wang, X., Wang, Z., Wang, K. -Y., Watanabe, K., Wei, J., Weimar, C., Weinrich, R., Wen, M. -S., Wheelan, K., Wicke, J., Wiemer, M., Wild, B., Wilke, A., Willems, S., Williams, M., Williams, D., Winkler, A., Wirtz, J. H., Witzenbichler, B., Wong, D. H. K., Lawrence Wong, K. S., Wong, B., Wozakowska-Kaplon, B., Wu, Z., Wu, S., Wyatt, N., Xu, Y., Xu, X., Yamada, A., Yamamoto, K., Yamanoue, H., Yamashita, T., Bryan Yan, P. Y., Yang, Y., Yang, T., Yao, J., Yarlagadda, C., Yeh, K. -H., Yotov, Y., Yvorra, S., Zahn, R., Zamorano, J., Zanini, R., Zarich, S., Zebrack, J., Zenin, S., Zeuthen, E. L., Zhang, X., Zhang, Q., Zhang, D., Zhang, H., Zhao, S., Zhao, X., Zheng, Y., Zheng, Q., Zhou, J., Zimmermann, S. L., Zimmermann, R., Zukerman, L. S., Zwaan van der, C., Huisman, M, Rothman, K, Paquette, M, Teutsch, C, Diener, H, Dubner, S, Halperin, J, Ma, C, Zint, K, Elsaesser, A, Bartels, D, Lip, G, Abban, D, Abdul, N, Abelson, M, Ackermann, A, Adams, F, Adams, L, Adragão, P, Ageno, W, Aggarwal, R, Agosti, S, Marin, J, Aguilar, F, Aguilar Linares, J, Aguinaga, L, Ahmad, Z, Ainsworth, P, Al Ghalayini, K, Al Ismail, S, Alasfar, A, Alawwa, A, Al Dallow, R, Alderson, L, Alexopoulos, D, Ali, A, Ali, M, Aliyar, P, Al Joundi, T, Al Mahameed, S, Almassi, H, Almuti, K, Al Obaidi, M, Alshehri, M, Altmann, U, Alves, A, Al Zoebi, A, Amara, W, Amelot, M, Amjadi, N, Ammirati, F, Andrawis, N, Angoulvant, D, Annoni, G, Ansalone, G, Antonescu, S, Ariani, M, Arias, J, Armero, S, Arora, R, Arora, C, Ashcraft, W, Aslam, M, Astesiano, A, Audouin, P, Augenbraun, C, Aydin, S, Azar, R, Azim, A, Aziz, S, Backes, L, Baig, M, Bains, S, Bakbak, A, Baker, S, Bakhtiar, K, Bala, R, Banayan, J, Bandh, S, Bando, S, Banerjee, S, Bank, A, Barbarash, O, Barón, G, Barr, C, Barrera, C, Barton, J, Kes, V, Baula, G, Bayeh, H, Bazargani, N, Behrens, S, Bell, A, Benezet Mazuecos, J, Benhalima, B, Berdagué, P, Berg van den, B, Bergen van, P, Berngard, E, Bernstein, R, Berrospi, P, Berti, S, Bertomeu, V, Berz, A, Bettencourt, P, Betzu, R, Beyer Westendorf, J, Bhagwat, R, Black, T, Blanco Ibaceta, J, Bloom, S, Blumberg, E, Bo, M, Bockisch, V, Bøhmer, E, Bongiorni, M, Boriani, G, Bosch, R, Boswijk, D, Bott, J, Bottacchi, E, Kalan, M, Brandes, A, Bratland, B, Brautigam, D, Breton, N, Brouwers, P, Browne, K, Bruguera, J, Brunehaut, M, Brunschwig, C, Buathier, H, Buhl, A, Bullinga, J, Butcher, K, Cabrera Honorio, J, Caccavo, A, Cadinot, D, Cai, S, Calvi, V, Camm, J, Candeias, R, Capo, J, Capucci, A, Cardoso, J, Duarte Vera, Y, Carlson, B, Carvalho, P, Cary, S, Casanova, R, Casu, G, Cattan, S, Cavallini, C, Cayla, G, Cha, T, Cha, K, Chaaban, S, Chae, J, Challappa, K, Chand, S, Chandrashekar, H, Chang, M, Charbel, P, Chartier, L, Chatterjee, K, Cheema, A, Chen, S, Chevallereau, P, Chiang, F, Chiarella, F, Chih Chan, L, Cho, Y, Choi, D, Chouinard, G, Danny, N, Chow, H, Chrysos, D, Chumakova, G, José Roberto Chuquiure Valenzuela, E, Cieza Lara, T, Nica, V, Ciobotaru, V, Cislowski, D, Citerne, O, Claus, M, Clay, A, Clifford, P, Cohen, S, Cohen, A, Colivicchi, F, Collins, R, Compton, S, Connors, S, Conti, A, Buenostro, G, Coodley, G, Cooper, M, Corbett, L, Corey, O, Coronel, J, Corrigan, J, Cotrina Pereyra, R, Cottin, Y, Coutu, B, Cracan, A, Crean, P, Crenshaw, J, Crijns, H, Crump, C, Cucher, F, Cudmore, D, Cui, L, Culp, J, Darius, H, Dary, P, Dascotte, O, Dauber, I, Davee, T, Davies, R, Davis, G, Davy, J, Dayer, M, De La Briolle, A, de Mora, M, De Teresa, E, De Wolf, L, Decoulx, E, Deepak, S, Defaye, P, Del Carpio Munoz, F, Brkljacic, D, Deluche, L, Destrac, S, Deumite, N, Di Legge, S, Dibon, O, Diemberger, I, Dillinger, J, Dionísio, P, Naydenov, S, Dotani, I, Dotcheva, E, D'Souza, A, Dubrey, S, Ducrocq, X, Dupljakov, D, Duthinh, V, Dutra, O, Dutta, D, Duvilla, N, Dy, J, Dziewas, R, Eaton, C, Eaves, W, Ebinger, M, Eck van, J, Edwards, T, Egocheaga, I, Ehrlich, C, Eisenberg, S, El Hallak, A, El Jabali, A, El Mahmoud, R, El Shahawy, M, Eldadah, Z, Elghelbazouri, F, Elhag, O, El Hamdani, M, Elias, D, Ellery, A, El Sayed, H, Elvan, A, Erickson, B, Espaliat, E, Essandoh, L, Everington, T, Evonich, R, Ezhov, A, Fácila, L, Farsad, R, Fayard, M, Fedele, F, Gomes Ferreira, L, Ferreira, D, Santos, J, Ferrier, A, Finsen, A, First, B, Fisher, R, Floyd, J, Folk, T, Fonseca, C, Fonseca, L, Forman, S, Forsgren, M, Foster, M, Foster, N, Frais, M, Frandsen, B, Frappé, T, Freixa, R, French, W, Freydlin, M, Frickel, S, Fruntelata, A, Fujii, S, Fujino, Y, Fukunaga, H, Furukawa, Y, Gabelmann, M, Gabris, M, Gadsbøll, N, Galin, P, Galinier, M, Ganim, R, Garcia, R, Quintana, A, Gartenlaub, O, Genz, C, Georger, F, Georges, J, Georgeson, S, Ghanbasha, A, Giedrimas, E, Gierba, M, Gillespie, E, Giniger, A, Gkotsis, A, Gmehling, J, Gniot, J, Goethals, P, Goldberg, R, Goldmann, B, Goldscher, D, Golitsyn, S, Gomez Lopez, E, Gomez Mesa, J, Gonzalez, E, Cocina, E, Juanatey, C, Gorbunov, V, Gordon, B, Gorka, H, Gornick, C, Gorog, D, Goss, F, Götte, A, Goube, P, Goudevenos, I, Goulden, D, Graham, B, Grande, A, Greco, C, Green, M, Greer, G, Gremmler, U, Grena, P, Grinshstein, Y, Grond, M, Gronda, E, Grondin, F, Grönefeld, G, Groot de, J, Guardigli, G, Guarnieri, T, Caiedo, C, Guignier, A, Gulizia, M, Gumbley, M, Gupta, D, Hack, T, Haerer, W, Hakas, J, Hall, C, Hampsey, J, Hananis, G, Hanbali, B, Handel, F, Hargrove, J, Hargroves, D, Harris, K, Hartley, D, Haruna, T, Hata, Y, Hayek, E, Healey, J, Hearne, S, Heggelund, G, Hemels, M, Hemery, Y, Henein, S, Henz, B, Her, S, Hermany, P, Hernandes, M, Higashino, Y, Hill, M, Hisadome, T, Hishida, E, Hitchcock, J, Hoffer, E, Hoghton, M, Holmes, C, Hong, S, Houppe Nousse, M, Howard, V, Hsu, L, Huang, C, Huckins, D, Huehnergarth, K, Huizenga, A, Huntley, R, Hussein, G, Hwang, G, Igbokidi, O, Iglesias, I, Ikpoh, M, Imberti, D, Ince, H, Indolfi, C, Ionova, T, Ip, J, Irles, D, Iseki, H, Ismail, Y, Israel, N, Isserman, S, Iteld, B, Ivanchura, G, Iyer, R, Iyer, V, Iza Villanueva, R, Jackson Voyzey, E, Jaffrani, N, Jäger, F, Jain, M, James, M, Jamon, Y, Jang, S, Pereira Jardim, C, Jarmukli, N, Jeanfreau, R, Jenkins, R, Jiang, X, Jiang, H, Jiang, T, Jiang, N, Jimenez, J, Jobe, R, Joffe, I, Johansson, B, Jones, N, Moura Jorge, J, Jouve, B, Jundi, M, Jung, W, Jung, B, Jung, K, Kabbani, S, Kabour, A, Kafkala, C, Kajiwara, K, Kalinina, L, Kampus, P, Kanda, J, Kapadia, S, Karim, A, Karolyi, L, Kashou, H, Kastrup, A, Katsivas, A, Kaufman, E, Kawai, K, Kawajiri, K, Kazmierski, J, Keeling, P, Kerfes, G, Kerr Saraiva, J, Ketova, G, Khaira, A, Khalid, M, Khludeeva, E, Khripun, A, Kim, D, Kim, N, Kim, K, Kim, Y, Kim, J, Kinova, E, Klein, A, Kleinschnitz, C, Kmetzo, J, Kneller, G, Knezevic, A, Koch, S, Koenig, K, Angela Koh, S, Köhrmann, M, Koons, J, Korabathina, R, Korennova, O, Koschutnik, M, Kosinski, E, Kovacic, D, Kowalczyk, J, Koziolova, N, Kragten, J, Krause, L, Kreidieh, I, Krenning, B, Krishnaswamy, K, Krysiak, W, Kuck, K, Kumar, S, Kümler, T, Kuniss, M, Kuo, J, Küppers, A, Kurrelmeyer, K, Kwan, T, Kyo, E, Labovitz, A, Lacroix, A, Lam, A, Lanas Zanetti, F, Landau, C, Landini, G, Lang, W, Larsen, T, Laske, V, Lavandier, K, Law, N, Lee, M, Lee, D, Leitão, A, Lejay, D, Lelonek, M, Lenarczyk, R, Leprince, P, Lequeux, B, Leschke, M, Ley, N, Li, Z, Li, Y, Li, X, Li, W, Liang, J, Lieber, I, Lillestol, M, Limon Rodriguez, R, Lin, H, Litchfield, J, Liu, Z, Liu, X, Liu, Y, Liu, F, Liu, W, Llamas Esperon, G, Llisterri, J, Lo, T, Lo, E, Lobos, J, Lodde, B, Loiselet, P, López Sendón, J, Lorga Filho, A, Lori, I, Luo, M, Lupovitch, S, Lyrer, P, Zuhairy, H, Ma, G, Ma, H, Madariaga, I, Maeno, K, Magnin, D, Mahmood, S, Mahood, K, Maid, G, Mainigi, S, Makaritsis, K, Maldonado Villalon, J, Malhotra, R, Malik, A, Mallecourt, C, Mallik, R, Manning, R, Manolis, A, Mantas, I, Manzur Jattin, F, Marcionni, N, Marín, F, Santana, A, Martinez, J, Martinez, L, Maskova, P, Hernández, N, Matskeplishvili, S, Matsuda, K, Mavri, A, May, E, Mayer, N, Mazon, P, Mcclure, J, Mccormack, T, Mcgarity, W, Mcguire, M, Mcintyre, H, Mclaughlin, P, Mclaurin, B, Medina Palomino, F, Mehta, P, Mehzad, R, Meinel, A, Melandri, F, Mena, A, Meno, H, Menzies, D, Metcalf, K, Meyer, B, Miarka, J, Mibach, F, Michalski, D, Michel, P, Chreih, R, Mikdadi, G, Mikhail, M, Mikus, M, Milicic, D, Militaru, C, Miller, G, Milonas, C, Minescu, B, Mintale, I, Miralles, A, Mirault, T, Mistry, D, Mitchell, G, Miu, N, Miyamoto, N, Moccetti, T, Mohammed, A, Nor, A, Molina de Salazar, D, Molon, G, Molony, D, Mondillo, S, Mont, L, Moodley, R, Moore, R, Ribeiro Moreira, D, Mori, K, Moriarty, A, Morka, J, Moschos, N, Mota Gomes, M, Mousallem, N, Moya, A, Mügge, A, Mulhearn, T, Muller, J, Muresan, C, Muse, D, Musial, W, Musumeci, F, Nadar, V, Nageh, T, Nair, P, Nakagawa, H, Nakamura, Y, Nakayama, T, Nam, K, Napalkov, D, Natarajan, I, Nayak, H, Nechvatal, L, Neiman, J, Nerheim, P, Neuenschwander, F, Nishida, K, Nizov, A, Novikova, T, Novo, S, Nowalany Kozielska, E, Nsah, E, Nunez Fragoso, J, Nyvad, O, de Los Rios Ibarra, M, O'Donnell, M, O'Donnell, P, Oh, D, Oh, Y, Daniel Oh, C, O'Hara, G, Oikonomou, K, Olalla, J, Olivari, Z, Oliver, R, Olympios, C, Osborne, J, Osca, J, Osman, R, Osunkoya, A, Padanilam, B, Panchenko, E, Pandey, A, Vicenzo de Paola, A, Paraschos, A, Pardell, H, Park, H, Park, J, Parkash, R, Parker, I, Parrens, E, Parris, R, Passamonti, E, Patel, J, Patel, R, Pentz, W, Persic, V, Perticone, F, Peters, P, Petkar, S, Pezo, L, Pham, D, Cao Phai, G, Phlaum, S, Pineau, J, Pineda Velez, A, Pini, R, Pinter, A, Pinto, F, Pirelli, S, Pivac, N, Pizzini, A, Pocanic, D, Calin Podoleanu, C, Polanczyk, C, Polasek, P, Poljakovic, Z, Pollock, S, Polo, J, Poock, J, Poppert, H, Porro, Y, Pose, A, Poulain, F, Poulard, J, Pouzar, J, Povolny, P, Pozzer, D, Pras, A, Prasad, N, Prevot, S, Protasov, K, Prunier, L, Puleo, J, Pye, M, Qaddoura, F, Quedillac, J, Raev, D, Rahimi, S, Raisaro, A, Rama, B, Ranadive, N, Randall, K, Ranjith, N, Raposo, N, Rashid, H, Raters, C, Rauch Kroehnert, U, Rebane, T, Regner, S, Renzi, M, Reyes Rocha, M, Reza, S, Ria, L, Richter, D, Rickli, H, Rickner, K, Rieker, W, Rigo, F, Ripoll, T, Fonteles Ritt, L, Roberts, D, Pascual, C, Briones, I, Reyes, H, Roelke, M, Roman, M, Romeo, F, Ronner, E, Ronziere, T, Rooyer, F, Rosenbaum, D, Roth, S, Rozkova, N, Rubacek, M, Rubalcava, F, Rubanenko, O, Rubin, A, Borret, M, Rybak, K, Sabbour, H, Morales, O, Sakai, T, Salacata, A, Salecker, I, Salem, A, Salfity, M, Salguero, R, Salvioni, A, Samson, M, Sanchez, G, Sandesara, C, Saporito, W, Sasaoka, T, Sattar, P, Savard, D, Scala, P, Scemama, J, Schaupp, T, Schellinger, P, Scherr, C, Schmitz, K, Schmitz, B, Schmitz, L, Schnitzler, R, Schnupp, S, Schoeniger, P, Schön, N, Schuster, S, Schwimmbeck, P, Seamark, C, Seebass, R, Seidl, K, Seidman, B, Sek, J, Sekaran, L, Seko, Y, Sepulveda Varela, P, Sevilla, B, Shah, V, Shah, A, Shah, N, Shanes, J, Sharareh, A, Sharma, V, Shaw, L, Shimizu, Y, Shimomura, H, Shin, D, Shin, E, Shite, J, Shoukfeh, M, Shoultz, C, Silver, F, Sime, I, Simmers, T, Singal, D, Singh, N, Siostrzonek, P, Sirajuddin, M, Skeppholm, M, Smadja, D, Smith, R, Smith, D, Soda, H, Sofley, C, Sokal, A, Sotolongo, R, de Souza, O, Sparby, J, Spinar, J, Sprigings, D, Spyropoulos, A, Stakos, D, Steinberg, A, Steinwender, C, Stergiou, G, Stites, H, Stoikov, A, Strasser, R, Streb, W, Styliadis, I, Su, G, Su, X, Suarez, R, Sudnik, W, Sueyoshi, A, Sukles, K, Sun, L, Suneja, R, Svensson, P, Ziekenhuis, A, Szavits Nossan, J, Taggeselle, J, Takagi, Y, Takhar, A, Tallet, J, Tamm, A, Tanaka, S, Tanaka, K, Tang, A, Tang, S, Tassinari, T, Tayama, S, Tayebjee, M, Tebbe, U, Teixeira, J, Tesloianu, D, Tessier, P, The, S, Thevenin, J, Thomas, H, Timsit, S, Topkis, R, Torosoff, M, Touze, E, Traissac, T, Trendafilova, E, Troyan, B, Tsai, W, Tse, H, Tsutsui, H, Tsutsui, T, Tuininga, Y, Turakhia, M, Turk, S, Turner, W, Tveit, A, Twiddy, S, Tytus, R, Ukrainski, G, Valdovinos Chavez, S, Van De Graaff, E, Vanacker, P, Vardas, P, Vargas, M, Vassilikos, V, Vazquez, J, Venkataraman, A, Verdecchia, P, Vester, E, Vial, H, Vinereanu, D, Vlastaris, A, Vogel, C, vom Dahl, J, von Mering, M, Vora, K, Wakefield, P, Walia, J, Walter, T, Wang, M, Wang, N, Wang, F, Wang, X, Wang, Z, Wang, K, Watanabe, K, Wei, J, Weimar, C, Weinrich, R, Wen, M, Wheelan, K, Wicke, J, Wiemer, M, Wild, B, Wilke, A, Willems, S, Williams, M, Williams, D, Winkler, A, Wirtz, J, Witzenbichler, B, Wong, D, Lawrence Wong, K, Wong, B, Wozakowska Kaplon, B, Wu, Z, Wu, S, Wyatt, N, Xu, Y, Xu, X, Yamada, A, Yamamoto, K, Yamanoue, H, Yamashita, T, Bryan Yan, P, Yang, Y, Yang, T, Yao, J, Yarlagadda, C, Yeh, K, Yotov, Y, Yvorra, S, Zahn, R, Zamorano, J, Zanini, R, Zarich, S, Zebrack, J, Zenin, S, Zeuthen, E, Zhang, X, Zhang, Q, Zhang, D, Zhang, H, Zhao, S, Zhao, X, Zheng, Y, Zheng, Q, Zhou, J, Zimmermann, S, Zimmermann, R, Zukerman, L, and Zwaan van der, C
- Subjects
Male ,oral anticoagulation ,Internationality ,Middle Aged ,registry ,Antithrombins ,Dabigatran ,Stroke ,Cross-Sectional Studies ,Fibrinolytic Agents ,Humans ,Female ,atrial fibrillation ,Prospective Studies ,Registries ,Cardiology and Cardiovascular Medicine ,Aged ,Atrial Fibrillation - Abstract
Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non–vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients’ baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score ≥2; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701)
- Published
- 2017
18. Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU
- Author
-
Vivas D, Roldán I, Ferrandis, R, Marín F, Roldán V, Tello-Montoliu A, Ruiz-Nodar JM, Gómez-Doblas JJ, Martín A, Llau JV, Ramos-Gallo MJ, Muñoz R, Arcelus JI, Leyva F, Alberca F, Oliva R, Gómez AM, Montero C, Arikan F, Ley L, Santos-Bueso E, Figuero E, Bujaldón A, Urbano J, Otero R, Hermida JF, Egocheaga I, Llisterri JL, Lobos JM, Serrano A, Madridano O, and Ferreiro JL
- Subjects
Antiagregación, Anticoagulación, Anticoagulation, Antiplatelet, Antithrombotic, Antitrombótico, Cirugía, Surgery - Abstract
During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most of the Spanish scientific societies of clinical specialities that may play a role in the patient-health care process during the perioperative or periprocedural period, is to recommend some simple and practical guidelines with a view to homogenizing daily clinical practice.
- Published
- 2018
19. Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting. The SILVER-AP study
- Author
-
de la Figuera, M, Cinza, S, Marin, N, Egocheaga, I, and Prieto, MA
- Subjects
Direct oral anticoagulants ,Anticoagulation ,Primary care ,Non-valvular atrial fibrillation - Abstract
Objective: To analyse the clinical characteristics and management of patients with non-valvular atrial fibrillation (NVAF) treated with direct oral anticoagulants (DOAC). Design: Observational, cross-sectional and multicentre study. Location: Autonomous Communities in which the general practitioner can prescribe DOAC (n = 9). Participants: The study included a total of 790 patients on chronic treatment with anticoagulants, and on whom therapy was changed, as well as being currently on treatment with DOAC for at least for 3 months. Main measures: A record was made of the sociodemographic and clinical management date. Results: Mean age was 78.6 +/- 8.4 years, and 50.5% of patients were men. Mean CHADS(2) score was 2.6 +/- 1.2, mean CHA(2)DS(2)-VASc score was 4.3 +/- 1.6, and the mean HAS-BLED score was 2.3 +/- 1.0. Mean duration of treatment with DOAC was 15.8 +/- 12.5 months. Rivaroxaban was the DOAC most frequently prescribed (57.8%), followed by dabigatran (23.7%), and apixaban (18.5%). Of the patients receiving rivaroxaban, 70.2% were taking the dose of 20 mg/daily. Of the patients receiving dabigatran, 41.7% were taking the dose of 150 mg twice daily, and in the case of apixaban, 56.2% were taking the dose of 5 mg twice daily. Satisfaction (ACTS Burdens scale 52.0 +/- 7.2 and ACTS Benefits scale 12.1 +/- 2.2), and therapeutic adherence (97.8% of patients took their medication regularly) with DOAC were high. Conclusions: Patients treated with DOAC in Spain have a high thromboembolic risk. A significant proportion of patients receive a lower dose of DOAC than that recommended according to their clinical profile. Satisfaction and medication adherence are high. (C) 2017 Elsevier Espana, S.L.U.
- Published
- 2018
20. Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVE', SECOT and AEU
- Author
-
Vivas, D, Roldan, I, Ferrandis, R, Marin, F, Roldan, V, Tello-Montoliu, A, Ruiz J, Jose Gomez-Doblas, J, Martin, A, Vicente Llau, J, Jose Ramos-Gallo, M, Munoz, R, Ignacio Arcelus, J, Leyva, F, Alberca, F, Oliva, R, Maria Gomez, A, Montero, C, Arikans, F, Ley, L, Santos-Buesou, E, Figuero, E, Bujaldon, A, Urbane, J, Otero, R, Francisco Hermida, J, Egocheaga, I, Luis Llisterri, J, Maria Lobos, J, Serrano, A, Madridano, O, Luis Ferreiro, J, Cassinello, C, Gomez-Luque, A, Hidalgo, F, Sierra, P, Marco P, Mateo Arranza, J, Palomo, V, Guerrero, A, Anguita, M, and Iniguez, A
- Subjects
Anticoagulation ,Antithrombotic ,Antiplatelet ,Surgery - Abstract
During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most of the Spanish scientific societies of clinical specialities that may play a role in the patient-health care process during the perioperative or periprocedural period, is to recommend some simple and practical guidelines with a view to homogenizing daily clinical practice. Full English text available from: www.revespcardiol.org/en (C) 2018 Sociedad Espafiola de Cardiologia. Published by Elsevier Espania, S.L.U. All rights reserved.
- Published
- 2018
21. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2
- Author
-
Huisman, M, Rothman, K, Paquette, M, Teutsch, C, Diener, H, Dubner, S, Halperin, J, Ma, C, Zint, K, Elsaesser, A, Bartels, D, Lip, G, Abban, D, Abdul, N, Abelson, M, Ackermann, A, Adams, F, Adams, L, Adragão, P, Ageno, W, Aggarwal, R, Agosti, S, Marin, J, Aguilar, F, Aguilar Linares, J, Aguinaga, L, Ahmad, Z, Ainsworth, P, Al Ghalayini, K, Al Ismail, S, Alasfar, A, Alawwa, A, Al Dallow, R, Alderson, L, Alexopoulos, D, Ali, A, Ali, M, Aliyar, P, Al Joundi, T, Al Mahameed, S, Almassi, H, Almuti, K, Al Obaidi, M, Alshehri, M, Altmann, U, Alves, A, Al Zoebi, A, Amara, W, Amelot, M, Amjadi, N, Ammirati, F, Andrawis, N, Angoulvant, D, Annoni, G, Ansalone, G, Antonescu, S, Ariani, M, Arias, J, Armero, S, Arora, R, Arora, C, Ashcraft, W, Aslam, M, Astesiano, A, Audouin, P, Augenbraun, C, Aydin, S, Azar, R, Azim, A, Aziz, S, Backes, L, Baig, M, Bains, S, Bakbak, A, Baker, S, Bakhtiar, K, Bala, R, Banayan, J, Bandh, S, Bando, S, Banerjee, S, Bank, A, Barbarash, O, Barón, G, Barr, C, Barrera, C, Barton, J, Kes, V, Baula, G, Bayeh, H, Bazargani, N, Behrens, S, Bell, A, Benezet Mazuecos, J, Benhalima, B, Berdagué, P, Berg van den, B, Bergen van, P, Berngard, E, Bernstein, R, Berrospi, P, Berti, S, Bertomeu, V, Berz, A, Bettencourt, P, Betzu, R, Beyer Westendorf, J, Bhagwat, R, Black, T, Blanco Ibaceta, J, Bloom, S, Blumberg, E, Bo, M, Bockisch, V, Bøhmer, E, Bongiorni, M, Boriani, G, Bosch, R, Boswijk, D, Bott, J, Bottacchi, E, Kalan, M, Brandes, A, Bratland, B, Brautigam, D, Breton, N, Brouwers, P, Browne, K, Bruguera, J, Brunehaut, M, Brunschwig, C, Buathier, H, Buhl, A, Bullinga, J, Butcher, K, Cabrera Honorio, J, Caccavo, A, Cadinot, D, Cai, S, Calvi, V, Camm, J, Candeias, R, Capo, J, Capucci, A, Cardoso, J, Duarte Vera, Y, Carlson, B, Carvalho, P, Cary, S, Casanova, R, Casu, G, Cattan, S, Cavallini, C, Cayla, G, Cha, T, Cha, K, Chaaban, S, Chae, J, Challappa, K, Chand, S, Chandrashekar, H, Chang, M, Charbel, P, Chartier, L, Chatterjee, K, Cheema, A, Chen, S, Chevallereau, P, Chiang, F, Chiarella, F, Chih Chan, L, Cho, Y, Choi, D, Chouinard, G, Danny, N, Chow, H, Chrysos, D, Chumakova, G, José Roberto Chuquiure Valenzuela, E, Cieza Lara, T, Nica, V, Ciobotaru, V, Cislowski, D, Citerne, O, Claus, M, Clay, A, Clifford, P, Cohen, S, Cohen, A, Colivicchi, F, Collins, R, Compton, S, Connors, S, Conti, A, Buenostro, G, Coodley, G, Cooper, M, Corbett, L, Corey, O, Coronel, J, Corrigan, J, Cotrina Pereyra, R, Cottin, Y, Coutu, B, Cracan, A, Crean, P, Crenshaw, J, Crijns, H, Crump, C, Cucher, F, Cudmore, D, Cui, L, Culp, J, Darius, H, Dary, P, Dascotte, O, Dauber, I, Davee, T, Davies, R, Davis, G, Davy, J, Dayer, M, De La Briolle, A, de Mora, M, De Teresa, E, De Wolf, L, Decoulx, E, Deepak, S, Defaye, P, Del Carpio Munoz, F, Brkljacic, D, Deluche, L, Destrac, S, Deumite, N, Di Legge, S, Dibon, O, Diemberger, I, Dillinger, J, Dionísio, P, Naydenov, S, Dotani, I, Dotcheva, E, D'Souza, A, Dubrey, S, Ducrocq, X, Dupljakov, D, Duthinh, V, Dutra, O, Dutta, D, Duvilla, N, Dy, J, Dziewas, R, Eaton, C, Eaves, W, Ebinger, M, Eck van, J, Edwards, T, Egocheaga, I, Ehrlich, C, Eisenberg, S, El Hallak, A, El Jabali, A, El Mahmoud, R, El Shahawy, M, Eldadah, Z, Elghelbazouri, F, Elhag, O, El Hamdani, M, Elias, D, Ellery, A, El Sayed, H, Elvan, A, Erickson, B, Espaliat, E, Essandoh, L, Everington, T, Evonich, R, Ezhov, A, Fácila, L, Farsad, R, Fayard, M, Fedele, F, Gomes Ferreira, L, Ferreira, D, Santos, J, Ferrier, A, Finsen, A, First, B, Fisher, R, Floyd, J, Folk, T, Fonseca, C, Fonseca, L, Forman, S, Forsgren, M, Foster, M, Foster, N, Frais, M, Frandsen, B, Frappé, T, Freixa, R, French, W, Freydlin, M, Frickel, S, Fruntelata, A, Fujii, S, Fujino, Y, Fukunaga, H, Furukawa, Y, Gabelmann, M, Gabris, M, Gadsbøll, N, Galin, P, Galinier, M, Ganim, R, Garcia, R, Quintana, A, Gartenlaub, O, Genz, C, Georger, F, Georges, J, Georgeson, S, Ghanbasha, A, Giedrimas, E, Gierba, M, Gillespie, E, Giniger, A, Gkotsis, A, Gmehling, J, Gniot, J, Goethals, P, Goldberg, R, Goldmann, B, Goldscher, D, Golitsyn, S, Gomez Lopez, E, Gomez Mesa, J, Gonzalez, E, Cocina, E, Juanatey, C, Gorbunov, V, Gordon, B, Gorka, H, Gornick, C, Gorog, D, Goss, F, Götte, A, Goube, P, Goudevenos, I, Goulden, D, Graham, B, Grande, A, Greco, C, Green, M, Greer, G, Gremmler, U, Grena, P, Grinshstein, Y, Grond, M, Gronda, E, Grondin, F, Grönefeld, G, Groot de, J, Guardigli, G, Guarnieri, T, Caiedo, C, Guignier, A, Gulizia, M, Gumbley, M, Gupta, D, Hack, T, Haerer, W, Hakas, J, Hall, C, Hampsey, J, Hananis, G, Hanbali, B, Handel, F, Hargrove, J, Hargroves, D, Harris, K, Hartley, D, Haruna, T, Hata, Y, Hayek, E, Healey, J, Hearne, S, Heggelund, G, Hemels, M, Hemery, Y, Henein, S, Henz, B, Her, S, Hermany, P, Hernandes, M, Higashino, Y, Hill, M, Hisadome, T, Hishida, E, Hitchcock, J, Hoffer, E, Hoghton, M, Holmes, C, Hong, S, Houppe Nousse, M, Howard, V, Hsu, L, Huang, C, Huckins, D, Huehnergarth, K, Huizenga, A, Huntley, R, Hussein, G, Hwang, G, Igbokidi, O, Iglesias, I, Ikpoh, M, Imberti, D, Ince, H, Indolfi, C, Ionova, T, Ip, J, Irles, D, Iseki, H, Ismail, Y, Israel, N, Isserman, S, Iteld, B, Ivanchura, G, Iyer, R, Iyer, V, Iza Villanueva, R, Jackson Voyzey, E, Jaffrani, N, Jäger, F, Jain, M, James, M, Jamon, Y, Jang, S, Pereira Jardim, C, Jarmukli, N, Jeanfreau, R, Jenkins, R, Jiang, X, Jiang, H, Jiang, T, Jiang, N, Jimenez, J, Jobe, R, Joffe, I, Johansson, B, Jones, N, Moura Jorge, J, Jouve, B, Jundi, M, Jung, W, Jung, B, Jung, K, Kabbani, S, Kabour, A, Kafkala, C, Kajiwara, K, Kalinina, L, Kampus, P, Kanda, J, Kapadia, S, Karim, A, Karolyi, L, Kashou, H, Kastrup, A, Katsivas, A, Kaufman, E, Kawai, K, Kawajiri, K, Kazmierski, J, Keeling, P, Kerfes, G, Kerr Saraiva, J, Ketova, G, Khaira, A, Khalid, M, Khludeeva, E, Khripun, A, Kim, D, Kim, N, Kim, K, Kim, Y, Kim, J, Kinova, E, Klein, A, Kleinschnitz, C, Kmetzo, J, Kneller, G, Knezevic, A, Koch, S, Koenig, K, Angela Koh, S, Köhrmann, M, Koons, J, Korabathina, R, Korennova, O, Koschutnik, M, Kosinski, E, Kovacic, D, Kowalczyk, J, Koziolova, N, Kragten, J, Krause, L, Kreidieh, I, Krenning, B, Krishnaswamy, K, Krysiak, W, Kuck, K, Kumar, S, Kümler, T, Kuniss, M, Kuo, J, Küppers, A, Kurrelmeyer, K, Kwan, T, Kyo, E, Labovitz, A, Lacroix, A, Lam, A, Lanas Zanetti, F, Landau, C, Landini, G, Lang, W, Larsen, T, Laske, V, Lavandier, K, Law, N, Lee, M, Lee, D, Leitão, A, Lejay, D, Lelonek, M, Lenarczyk, R, Leprince, P, Lequeux, B, Leschke, M, Ley, N, Li, Z, Li, Y, Li, X, Li, W, Liang, J, Lieber, I, Lillestol, M, Limon Rodriguez, R, Lin, H, Litchfield, J, Liu, Z, Liu, X, Liu, Y, Liu, F, Liu, W, Llamas Esperon, G, Llisterri, J, Lo, T, Lo, E, Lobos, J, Lodde, B, Loiselet, P, López Sendón, J, Lorga Filho, A, Lori, I, Luo, M, Lupovitch, S, Lyrer, P, Zuhairy, H, Ma, G, Ma, H, Madariaga, I, Maeno, K, Magnin, D, Mahmood, S, Mahood, K, Maid, G, Mainigi, S, Makaritsis, K, Maldonado Villalon, J, Malhotra, R, Malik, A, Mallecourt, C, Mallik, R, Manning, R, Manolis, A, Mantas, I, Manzur Jattin, F, Marcionni, N, Marín, F, Santana, A, Martinez, J, Martinez, L, Maskova, P, Hernández, N, Matskeplishvili, S, Matsuda, K, Mavri, A, May, E, Mayer, N, Mazon, P, Mcclure, J, Mccormack, T, Mcgarity, W, Mcguire, M, Mcintyre, H, Mclaughlin, P, Mclaurin, B, Medina Palomino, F, Mehta, P, Mehzad, R, Meinel, A, Melandri, F, Mena, A, Meno, H, Menzies, D, Metcalf, K, Meyer, B, Miarka, J, Mibach, F, Michalski, D, Michel, P, Chreih, R, Mikdadi, G, Mikhail, M, Mikus, M, Milicic, D, Militaru, C, Miller, G, Milonas, C, Minescu, B, Mintale, I, Miralles, A, Mirault, T, Mistry, D, Mitchell, G, Miu, N, Miyamoto, N, Moccetti, T, Mohammed, A, Nor, A, Molina de Salazar, D, Molon, G, Molony, D, Mondillo, S, Mont, L, Moodley, R, Moore, R, Ribeiro Moreira, D, Mori, K, Moriarty, A, Morka, J, Moschos, N, Mota Gomes, M, Mousallem, N, Moya, A, Mügge, A, Mulhearn, T, Muller, J, Muresan, C, Muse, D, Musial, W, Musumeci, F, Nadar, V, Nageh, T, Nair, P, Nakagawa, H, Nakamura, Y, Nakayama, T, Nam, K, Napalkov, D, Natarajan, I, Nayak, H, Nechvatal, L, Neiman, J, Nerheim, P, Neuenschwander, F, Nishida, K, Nizov, A, Novikova, T, Novo, S, Nowalany Kozielska, E, Nsah, E, Nunez Fragoso, J, Nyvad, O, de Los Rios Ibarra, M, O'Donnell, M, O'Donnell, P, Oh, D, Oh, Y, Daniel Oh, C, O'Hara, G, Oikonomou, K, Olalla, J, Olivari, Z, Oliver, R, Olympios, C, Osborne, J, Osca, J, Osman, R, Osunkoya, A, Padanilam, B, Panchenko, E, Pandey, A, Vicenzo de Paola, A, Paraschos, A, Pardell, H, Park, H, Park, J, Parkash, R, Parker, I, Parrens, E, Parris, R, Passamonti, E, Patel, J, Patel, R, Pentz, W, Persic, V, Perticone, F, Peters, P, Petkar, S, Pezo, L, Pham, D, Cao Phai, G, Phlaum, S, Pineau, J, Pineda Velez, A, Pini, R, Pinter, A, Pinto, F, Pirelli, S, Pivac, N, Pizzini, A, Pocanic, D, Calin Podoleanu, C, Polanczyk, C, Polasek, P, Poljakovic, Z, Pollock, S, Polo, J, Poock, J, Poppert, H, Porro, Y, Pose, A, Poulain, F, Poulard, J, Pouzar, J, Povolny, P, Pozzer, D, Pras, A, Prasad, N, Prevot, S, Protasov, K, Prunier, L, Puleo, J, Pye, M, Qaddoura, F, Quedillac, J, Raev, D, Rahimi, S, Raisaro, A, Rama, B, Ranadive, N, Randall, K, Ranjith, N, Raposo, N, Rashid, H, Raters, C, Rauch Kroehnert, U, Rebane, T, Regner, S, Renzi, M, Reyes Rocha, M, Reza, S, Ria, L, Richter, D, Rickli, H, Rickner, K, Rieker, W, Rigo, F, Ripoll, T, Fonteles Ritt, L, Roberts, D, Pascual, C, Briones, I, Reyes, H, Roelke, M, Roman, M, Romeo, F, Ronner, E, Ronziere, T, Rooyer, F, Rosenbaum, D, Roth, S, Rozkova, N, Rubacek, M, Rubalcava, F, Rubanenko, O, Rubin, A, Borret, M, Rybak, K, Sabbour, H, Morales, O, Sakai, T, Salacata, A, Salecker, I, Salem, A, Salfity, M, Salguero, R, Salvioni, A, Samson, M, Sanchez, G, Sandesara, C, Saporito, W, Sasaoka, T, Sattar, P, Savard, D, Scala, P, Scemama, J, Schaupp, T, Schellinger, P, Scherr, C, Schmitz, K, Schmitz, B, Schmitz, L, Schnitzler, R, Schnupp, S, Schoeniger, P, Schön, N, Schuster, S, Schwimmbeck, P, Seamark, C, Seebass, R, Seidl, K, Seidman, B, Sek, J, Sekaran, L, Seko, Y, Sepulveda Varela, P, Sevilla, B, Shah, V, Shah, A, Shah, N, Shanes, J, Sharareh, A, Sharma, V, Shaw, L, Shimizu, Y, Shimomura, H, Shin, D, Shin, E, Shite, J, Shoukfeh, M, Shoultz, C, Silver, F, Sime, I, Simmers, T, Singal, D, Singh, N, Siostrzonek, P, Sirajuddin, M, Skeppholm, M, Smadja, D, Smith, R, Smith, D, Soda, H, Sofley, C, Sokal, A, Sotolongo, R, de Souza, O, Sparby, J, Spinar, J, Sprigings, D, Spyropoulos, A, Stakos, D, Steinberg, A, Steinwender, C, Stergiou, G, Stites, H, Stoikov, A, Strasser, R, Streb, W, Styliadis, I, Su, G, Su, X, Suarez, R, Sudnik, W, Sueyoshi, A, Sukles, K, Sun, L, Suneja, R, Svensson, P, Ziekenhuis, A, Szavits Nossan, J, Taggeselle, J, Takagi, Y, Takhar, A, Tallet, J, Tamm, A, Tanaka, S, Tanaka, K, Tang, A, Tang, S, Tassinari, T, Tayama, S, Tayebjee, M, Tebbe, U, Teixeira, J, Tesloianu, D, Tessier, P, The, S, Thevenin, J, Thomas, H, Timsit, S, Topkis, R, Torosoff, M, Touze, E, Traissac, T, Trendafilova, E, Troyan, B, Tsai, W, Tse, H, Tsutsui, H, Tsutsui, T, Tuininga, Y, Turakhia, M, Turk, S, Turner, W, Tveit, A, Twiddy, S, Tytus, R, Ukrainski, G, Valdovinos Chavez, S, Van De Graaff, E, Vanacker, P, Vardas, P, Vargas, M, Vassilikos, V, Vazquez, J, Venkataraman, A, Verdecchia, P, Vester, E, Vial, H, Vinereanu, D, Vlastaris, A, Vogel, C, vom Dahl, J, von Mering, M, Vora, K, Wakefield, P, Walia, J, Walter, T, Wang, M, Wang, N, Wang, F, Wang, X, Wang, Z, Wang, K, Watanabe, K, Wei, J, Weimar, C, Weinrich, R, Wen, M, Wheelan, K, Wicke, J, Wiemer, M, Wild, B, Wilke, A, Willems, S, Williams, M, Williams, D, Winkler, A, Wirtz, J, Witzenbichler, B, Wong, D, Lawrence Wong, K, Wong, B, Wozakowska Kaplon, B, Wu, Z, Wu, S, Wyatt, N, Xu, Y, Xu, X, Yamada, A, Yamamoto, K, Yamanoue, H, Yamashita, T, Bryan Yan, P, Yang, Y, Yang, T, Yao, J, Yarlagadda, C, Yeh, K, Yotov, Y, Yvorra, S, Zahn, R, Zamorano, J, Zanini, R, Zarich, S, Zebrack, J, Zenin, S, Zeuthen, E, Zhang, X, Zhang, Q, Zhang, D, Zhang, H, Zhao, S, Zhao, X, Zheng, Y, Zheng, Q, Zhou, J, Zimmermann, S, Zimmermann, R, Zukerman, L, Zwaan van der, C, Zwaan van der, C., ANNONI, GIORGIO, Huisman, M, Rothman, K, Paquette, M, Teutsch, C, Diener, H, Dubner, S, Halperin, J, Ma, C, Zint, K, Elsaesser, A, Bartels, D, Lip, G, Abban, D, Abdul, N, Abelson, M, Ackermann, A, Adams, F, Adams, L, Adragão, P, Ageno, W, Aggarwal, R, Agosti, S, Marin, J, Aguilar, F, Aguilar Linares, J, Aguinaga, L, Ahmad, Z, Ainsworth, P, Al Ghalayini, K, Al Ismail, S, Alasfar, A, Alawwa, A, Al Dallow, R, Alderson, L, Alexopoulos, D, Ali, A, Ali, M, Aliyar, P, Al Joundi, T, Al Mahameed, S, Almassi, H, Almuti, K, Al Obaidi, M, Alshehri, M, Altmann, U, Alves, A, Al Zoebi, A, Amara, W, Amelot, M, Amjadi, N, Ammirati, F, Andrawis, N, Angoulvant, D, Annoni, G, Ansalone, G, Antonescu, S, Ariani, M, Arias, J, Armero, S, Arora, R, Arora, C, Ashcraft, W, Aslam, M, Astesiano, A, Audouin, P, Augenbraun, C, Aydin, S, Azar, R, Azim, A, Aziz, S, Backes, L, Baig, M, Bains, S, Bakbak, A, Baker, S, Bakhtiar, K, Bala, R, Banayan, J, Bandh, S, Bando, S, Banerjee, S, Bank, A, Barbarash, O, Barón, G, Barr, C, Barrera, C, Barton, J, Kes, V, Baula, G, Bayeh, H, Bazargani, N, Behrens, S, Bell, A, Benezet Mazuecos, J, Benhalima, B, Berdagué, P, Berg van den, B, Bergen van, P, Berngard, E, Bernstein, R, Berrospi, P, Berti, S, Bertomeu, V, Berz, A, Bettencourt, P, Betzu, R, Beyer Westendorf, J, Bhagwat, R, Black, T, Blanco Ibaceta, J, Bloom, S, Blumberg, E, Bo, M, Bockisch, V, Bøhmer, E, Bongiorni, M, Boriani, G, Bosch, R, Boswijk, D, Bott, J, Bottacchi, E, Kalan, M, Brandes, A, Bratland, B, Brautigam, D, Breton, N, Brouwers, P, Browne, K, Bruguera, J, Brunehaut, M, Brunschwig, C, Buathier, H, Buhl, A, Bullinga, J, Butcher, K, Cabrera Honorio, J, Caccavo, A, Cadinot, D, Cai, S, Calvi, V, Camm, J, Candeias, R, Capo, J, Capucci, A, Cardoso, J, Duarte Vera, Y, Carlson, B, Carvalho, P, Cary, S, Casanova, R, Casu, G, Cattan, S, Cavallini, C, Cayla, G, Cha, T, Cha, K, Chaaban, S, Chae, J, Challappa, K, Chand, S, Chandrashekar, H, Chang, M, Charbel, P, Chartier, L, Chatterjee, K, Cheema, A, Chen, S, Chevallereau, P, Chiang, F, Chiarella, F, Chih Chan, L, Cho, Y, Choi, D, Chouinard, G, Danny, N, Chow, H, Chrysos, D, Chumakova, G, José Roberto Chuquiure Valenzuela, E, Cieza Lara, T, Nica, V, Ciobotaru, V, Cislowski, D, Citerne, O, Claus, M, Clay, A, Clifford, P, Cohen, S, Cohen, A, Colivicchi, F, Collins, R, Compton, S, Connors, S, Conti, A, Buenostro, G, Coodley, G, Cooper, M, Corbett, L, Corey, O, Coronel, J, Corrigan, J, Cotrina Pereyra, R, Cottin, Y, Coutu, B, Cracan, A, Crean, P, Crenshaw, J, Crijns, H, Crump, C, Cucher, F, Cudmore, D, Cui, L, Culp, J, Darius, H, Dary, P, Dascotte, O, Dauber, I, Davee, T, Davies, R, Davis, G, Davy, J, Dayer, M, De La Briolle, A, de Mora, M, De Teresa, E, De Wolf, L, Decoulx, E, Deepak, S, Defaye, P, Del Carpio Munoz, F, Brkljacic, D, Deluche, L, Destrac, S, Deumite, N, Di Legge, S, Dibon, O, Diemberger, I, Dillinger, J, Dionísio, P, Naydenov, S, Dotani, I, Dotcheva, E, D'Souza, A, Dubrey, S, Ducrocq, X, Dupljakov, D, Duthinh, V, Dutra, O, Dutta, D, Duvilla, N, Dy, J, Dziewas, R, Eaton, C, Eaves, W, Ebinger, M, Eck van, J, Edwards, T, Egocheaga, I, Ehrlich, C, Eisenberg, S, El Hallak, A, El Jabali, A, El Mahmoud, R, El Shahawy, M, Eldadah, Z, Elghelbazouri, F, Elhag, O, El Hamdani, M, Elias, D, Ellery, A, El Sayed, H, Elvan, A, Erickson, B, Espaliat, E, Essandoh, L, Everington, T, Evonich, R, Ezhov, A, Fácila, L, Farsad, R, Fayard, M, Fedele, F, Gomes Ferreira, L, Ferreira, D, Santos, J, Ferrier, A, Finsen, A, First, B, Fisher, R, Floyd, J, Folk, T, Fonseca, C, Fonseca, L, Forman, S, Forsgren, M, Foster, M, Foster, N, Frais, M, Frandsen, B, Frappé, T, Freixa, R, French, W, Freydlin, M, Frickel, S, Fruntelata, A, Fujii, S, Fujino, Y, Fukunaga, H, Furukawa, Y, Gabelmann, M, Gabris, M, Gadsbøll, N, Galin, P, Galinier, M, Ganim, R, Garcia, R, Quintana, A, Gartenlaub, O, Genz, C, Georger, F, Georges, J, Georgeson, S, Ghanbasha, A, Giedrimas, E, Gierba, M, Gillespie, E, Giniger, A, Gkotsis, A, Gmehling, J, Gniot, J, Goethals, P, Goldberg, R, Goldmann, B, Goldscher, D, Golitsyn, S, Gomez Lopez, E, Gomez Mesa, J, Gonzalez, E, Cocina, E, Juanatey, C, Gorbunov, V, Gordon, B, Gorka, H, Gornick, C, Gorog, D, Goss, F, Götte, A, Goube, P, Goudevenos, I, Goulden, D, Graham, B, Grande, A, Greco, C, Green, M, Greer, G, Gremmler, U, Grena, P, Grinshstein, Y, Grond, M, Gronda, E, Grondin, F, Grönefeld, G, Groot de, J, Guardigli, G, Guarnieri, T, Caiedo, C, Guignier, A, Gulizia, M, Gumbley, M, Gupta, D, Hack, T, Haerer, W, Hakas, J, Hall, C, Hampsey, J, Hananis, G, Hanbali, B, Handel, F, Hargrove, J, Hargroves, D, Harris, K, Hartley, D, Haruna, T, Hata, Y, Hayek, E, Healey, J, Hearne, S, Heggelund, G, Hemels, M, Hemery, Y, Henein, S, Henz, B, Her, S, Hermany, P, Hernandes, M, Higashino, Y, Hill, M, Hisadome, T, Hishida, E, Hitchcock, J, Hoffer, E, Hoghton, M, Holmes, C, Hong, S, Houppe Nousse, M, Howard, V, Hsu, L, Huang, C, Huckins, D, Huehnergarth, K, Huizenga, A, Huntley, R, Hussein, G, Hwang, G, Igbokidi, O, Iglesias, I, Ikpoh, M, Imberti, D, Ince, H, Indolfi, C, Ionova, T, Ip, J, Irles, D, Iseki, H, Ismail, Y, Israel, N, Isserman, S, Iteld, B, Ivanchura, G, Iyer, R, Iyer, V, Iza Villanueva, R, Jackson Voyzey, E, Jaffrani, N, Jäger, F, Jain, M, James, M, Jamon, Y, Jang, S, Pereira Jardim, C, Jarmukli, N, Jeanfreau, R, Jenkins, R, Jiang, X, Jiang, H, Jiang, T, Jiang, N, Jimenez, J, Jobe, R, Joffe, I, Johansson, B, Jones, N, Moura Jorge, J, Jouve, B, Jundi, M, Jung, W, Jung, B, Jung, K, Kabbani, S, Kabour, A, Kafkala, C, Kajiwara, K, Kalinina, L, Kampus, P, Kanda, J, Kapadia, S, Karim, A, Karolyi, L, Kashou, H, Kastrup, A, Katsivas, A, Kaufman, E, Kawai, K, Kawajiri, K, Kazmierski, J, Keeling, P, Kerfes, G, Kerr Saraiva, J, Ketova, G, Khaira, A, Khalid, M, Khludeeva, E, Khripun, A, Kim, D, Kim, N, Kim, K, Kim, Y, Kim, J, Kinova, E, Klein, A, Kleinschnitz, C, Kmetzo, J, Kneller, G, Knezevic, A, Koch, S, Koenig, K, Angela Koh, S, Köhrmann, M, Koons, J, Korabathina, R, Korennova, O, Koschutnik, M, Kosinski, E, Kovacic, D, Kowalczyk, J, Koziolova, N, Kragten, J, Krause, L, Kreidieh, I, Krenning, B, Krishnaswamy, K, Krysiak, W, Kuck, K, Kumar, S, Kümler, T, Kuniss, M, Kuo, J, Küppers, A, Kurrelmeyer, K, Kwan, T, Kyo, E, Labovitz, A, Lacroix, A, Lam, A, Lanas Zanetti, F, Landau, C, Landini, G, Lang, W, Larsen, T, Laske, V, Lavandier, K, Law, N, Lee, M, Lee, D, Leitão, A, Lejay, D, Lelonek, M, Lenarczyk, R, Leprince, P, Lequeux, B, Leschke, M, Ley, N, Li, Z, Li, Y, Li, X, Li, W, Liang, J, Lieber, I, Lillestol, M, Limon Rodriguez, R, Lin, H, Litchfield, J, Liu, Z, Liu, X, Liu, Y, Liu, F, Liu, W, Llamas Esperon, G, Llisterri, J, Lo, T, Lo, E, Lobos, J, Lodde, B, Loiselet, P, López Sendón, J, Lorga Filho, A, Lori, I, Luo, M, Lupovitch, S, Lyrer, P, Zuhairy, H, Ma, G, Ma, H, Madariaga, I, Maeno, K, Magnin, D, Mahmood, S, Mahood, K, Maid, G, Mainigi, S, Makaritsis, K, Maldonado Villalon, J, Malhotra, R, Malik, A, Mallecourt, C, Mallik, R, Manning, R, Manolis, A, Mantas, I, Manzur Jattin, F, Marcionni, N, Marín, F, Santana, A, Martinez, J, Martinez, L, Maskova, P, Hernández, N, Matskeplishvili, S, Matsuda, K, Mavri, A, May, E, Mayer, N, Mazon, P, Mcclure, J, Mccormack, T, Mcgarity, W, Mcguire, M, Mcintyre, H, Mclaughlin, P, Mclaurin, B, Medina Palomino, F, Mehta, P, Mehzad, R, Meinel, A, Melandri, F, Mena, A, Meno, H, Menzies, D, Metcalf, K, Meyer, B, Miarka, J, Mibach, F, Michalski, D, Michel, P, Chreih, R, Mikdadi, G, Mikhail, M, Mikus, M, Milicic, D, Militaru, C, Miller, G, Milonas, C, Minescu, B, Mintale, I, Miralles, A, Mirault, T, Mistry, D, Mitchell, G, Miu, N, Miyamoto, N, Moccetti, T, Mohammed, A, Nor, A, Molina de Salazar, D, Molon, G, Molony, D, Mondillo, S, Mont, L, Moodley, R, Moore, R, Ribeiro Moreira, D, Mori, K, Moriarty, A, Morka, J, Moschos, N, Mota Gomes, M, Mousallem, N, Moya, A, Mügge, A, Mulhearn, T, Muller, J, Muresan, C, Muse, D, Musial, W, Musumeci, F, Nadar, V, Nageh, T, Nair, P, Nakagawa, H, Nakamura, Y, Nakayama, T, Nam, K, Napalkov, D, Natarajan, I, Nayak, H, Nechvatal, L, Neiman, J, Nerheim, P, Neuenschwander, F, Nishida, K, Nizov, A, Novikova, T, Novo, S, Nowalany Kozielska, E, Nsah, E, Nunez Fragoso, J, Nyvad, O, de Los Rios Ibarra, M, O'Donnell, M, O'Donnell, P, Oh, D, Oh, Y, Daniel Oh, C, O'Hara, G, Oikonomou, K, Olalla, J, Olivari, Z, Oliver, R, Olympios, C, Osborne, J, Osca, J, Osman, R, Osunkoya, A, Padanilam, B, Panchenko, E, Pandey, A, Vicenzo de Paola, A, Paraschos, A, Pardell, H, Park, H, Park, J, Parkash, R, Parker, I, Parrens, E, Parris, R, Passamonti, E, Patel, J, Patel, R, Pentz, W, Persic, V, Perticone, F, Peters, P, Petkar, S, Pezo, L, Pham, D, Cao Phai, G, Phlaum, S, Pineau, J, Pineda Velez, A, Pini, R, Pinter, A, Pinto, F, Pirelli, S, Pivac, N, Pizzini, A, Pocanic, D, Calin Podoleanu, C, Polanczyk, C, Polasek, P, Poljakovic, Z, Pollock, S, Polo, J, Poock, J, Poppert, H, Porro, Y, Pose, A, Poulain, F, Poulard, J, Pouzar, J, Povolny, P, Pozzer, D, Pras, A, Prasad, N, Prevot, S, Protasov, K, Prunier, L, Puleo, J, Pye, M, Qaddoura, F, Quedillac, J, Raev, D, Rahimi, S, Raisaro, A, Rama, B, Ranadive, N, Randall, K, Ranjith, N, Raposo, N, Rashid, H, Raters, C, Rauch Kroehnert, U, Rebane, T, Regner, S, Renzi, M, Reyes Rocha, M, Reza, S, Ria, L, Richter, D, Rickli, H, Rickner, K, Rieker, W, Rigo, F, Ripoll, T, Fonteles Ritt, L, Roberts, D, Pascual, C, Briones, I, Reyes, H, Roelke, M, Roman, M, Romeo, F, Ronner, E, Ronziere, T, Rooyer, F, Rosenbaum, D, Roth, S, Rozkova, N, Rubacek, M, Rubalcava, F, Rubanenko, O, Rubin, A, Borret, M, Rybak, K, Sabbour, H, Morales, O, Sakai, T, Salacata, A, Salecker, I, Salem, A, Salfity, M, Salguero, R, Salvioni, A, Samson, M, Sanchez, G, Sandesara, C, Saporito, W, Sasaoka, T, Sattar, P, Savard, D, Scala, P, Scemama, J, Schaupp, T, Schellinger, P, Scherr, C, Schmitz, K, Schmitz, B, Schmitz, L, Schnitzler, R, Schnupp, S, Schoeniger, P, Schön, N, Schuster, S, Schwimmbeck, P, Seamark, C, Seebass, R, Seidl, K, Seidman, B, Sek, J, Sekaran, L, Seko, Y, Sepulveda Varela, P, Sevilla, B, Shah, V, Shah, A, Shah, N, Shanes, J, Sharareh, A, Sharma, V, Shaw, L, Shimizu, Y, Shimomura, H, Shin, D, Shin, E, Shite, J, Shoukfeh, M, Shoultz, C, Silver, F, Sime, I, Simmers, T, Singal, D, Singh, N, Siostrzonek, P, Sirajuddin, M, Skeppholm, M, Smadja, D, Smith, R, Smith, D, Soda, H, Sofley, C, Sokal, A, Sotolongo, R, de Souza, O, Sparby, J, Spinar, J, Sprigings, D, Spyropoulos, A, Stakos, D, Steinberg, A, Steinwender, C, Stergiou, G, Stites, H, Stoikov, A, Strasser, R, Streb, W, Styliadis, I, Su, G, Su, X, Suarez, R, Sudnik, W, Sueyoshi, A, Sukles, K, Sun, L, Suneja, R, Svensson, P, Ziekenhuis, A, Szavits Nossan, J, Taggeselle, J, Takagi, Y, Takhar, A, Tallet, J, Tamm, A, Tanaka, S, Tanaka, K, Tang, A, Tang, S, Tassinari, T, Tayama, S, Tayebjee, M, Tebbe, U, Teixeira, J, Tesloianu, D, Tessier, P, The, S, Thevenin, J, Thomas, H, Timsit, S, Topkis, R, Torosoff, M, Touze, E, Traissac, T, Trendafilova, E, Troyan, B, Tsai, W, Tse, H, Tsutsui, H, Tsutsui, T, Tuininga, Y, Turakhia, M, Turk, S, Turner, W, Tveit, A, Twiddy, S, Tytus, R, Ukrainski, G, Valdovinos Chavez, S, Van De Graaff, E, Vanacker, P, Vardas, P, Vargas, M, Vassilikos, V, Vazquez, J, Venkataraman, A, Verdecchia, P, Vester, E, Vial, H, Vinereanu, D, Vlastaris, A, Vogel, C, vom Dahl, J, von Mering, M, Vora, K, Wakefield, P, Walia, J, Walter, T, Wang, M, Wang, N, Wang, F, Wang, X, Wang, Z, Wang, K, Watanabe, K, Wei, J, Weimar, C, Weinrich, R, Wen, M, Wheelan, K, Wicke, J, Wiemer, M, Wild, B, Wilke, A, Willems, S, Williams, M, Williams, D, Winkler, A, Wirtz, J, Witzenbichler, B, Wong, D, Lawrence Wong, K, Wong, B, Wozakowska Kaplon, B, Wu, Z, Wu, S, Wyatt, N, Xu, Y, Xu, X, Yamada, A, Yamamoto, K, Yamanoue, H, Yamashita, T, Bryan Yan, P, Yang, Y, Yang, T, Yao, J, Yarlagadda, C, Yeh, K, Yotov, Y, Yvorra, S, Zahn, R, Zamorano, J, Zanini, R, Zarich, S, Zebrack, J, Zenin, S, Zeuthen, E, Zhang, X, Zhang, Q, Zhang, D, Zhang, H, Zhao, S, Zhao, X, Zheng, Y, Zheng, Q, Zhou, J, Zimmermann, S, Zimmermann, R, Zukerman, L, Zwaan van der, C, Zwaan van der, C., and ANNONI, GIORGIO
- Abstract
Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non–vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients’ baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score ≥2; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients rece
- Published
- 2017
22. GENDER DIFFERENCES AND CLINICAL PROFILE OF HYPERTENSIVE PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE: PP.28.107
- Author
-
Gijón, T, primary, Morón, I, additional, Palau, J, additional, Egocheaga, I, additional, Gómez, O, additional, Díaz, A, additional, Pitillas, I, additional, Rua, T, additional, and Valero, B, additional
- Published
- 2010
- Full Text
- View/download PDF
23. STROKE PREVALENCE AND RISK FACTOR CONTROL IN HYPERTENSIVE PATIENTS: PP.4.149
- Author
-
Gijón, T, primary, Pitillas, I, additional, Ramírez, M, additional, Jones, S, additional, Minguela, E, additional, Morón, I, additional, Díaz, A, additional, Gómez, O, additional, Palau, J, additional, and Egocheaga, I, additional
- Published
- 2010
- Full Text
- View/download PDF
24. Prevalence and clinical features of microalbuminuria in a large hypertensive sample. Relationship with the severity of blood pressure elevation and other cardiovascular risk factors
- Author
-
DELASIERRA, A, primary, EGOCHEAGA, I, additional, FERNANDEZLAVANDERA, C, additional, ANTONIO, M, additional, AGUILERA, M, additional, and TABOADA, J, additional
- Published
- 2005
- Full Text
- View/download PDF
25. INFLUENCE OF THE BODY MASS INDEX IN THE LEFT VENTRICULAR GEOMETRY OF ESSENTIAL HYPERTENSIVES
- Author
-
Martel, N., primary, Pinilla, C. Fernandez, additional, Avila, M., additional, Egocheaga, I., additional, Rodrigo, J. L., additional, Aubele, A. L., additional, Fernandez-Cruz, A., additional, and Luque, M., additional
- Published
- 2000
- Full Text
- View/download PDF
26. D69: Antihypertensive efficacy of amlodipine in high and low sodium diet.
- Author
-
Luque, M., Fernandez Pinilla, C., Egocheaga, I., Fernandez Cacao, L., Lopez Eady, M.D., Avila, M., Fernandez-Cruz, A., and Martell, N.
- Published
- 1997
- Full Text
- View/download PDF
27. Adherence to periprocedural antithrombotic treatment recommendations and its prognostic impact in patients with high ischemic and hemorrhagic risk.
- Author
-
Anguita-Gámez M, Vivas D, Ferrandis R, Esteve-Pastor MA, González-Manzanares R, Echeverri M, Igualada J, Egocheaga I, Nozal-Mateo B, Abad-Motos A, Figuero E, Bouzó-Molina N, Lozano T, Álvarez-Ortega C, Torres J, Descalzo MJ, Catalá JC, Martín-Rioboo E, Moliner A, Rodríguez-Contreras R, Carnero-Alcázar M, Marín F, and Anguita M
- Abstract
Introduction and Objectives: To analyze the clinical impact of the inappropriate use of antithrombotic treatment in patients with high ischemic or hemorrhagic risk during the periprocedural/perisurgical period in Spain., Methods: Prospective multicenter observational registry of patients receiving antiplatelet and/or anticoagulant therapy who required an intervention. The incidence of 30-day events was compared based on the peri-intervention management of antithrombotic treatment and the patients' risk classification (high vs. moderate-to-low risk). The primary endpoint was a composite of death, cardiovascular ischemic events, or bleeding events classified as BARC 2 or higher., Results: A total of 1152 patients were analyzed. Of these, 1.9% had both high ischemic and hemorrhagic risks (A);10.8% had high ischemic risk and low-to-moderate hemorrhagic risk (B); 12% had high hemorrhagic risk and low-to-moderate ischemic risk (C); and 75.3% had both low-to-moderate risks (D). The prevalence of inappropriate treatment was higher in the subgroup with high hemorrhagic risk and low-to-moderate ischemic risk (C) (62.6% vs 40.9% in subgroup A; P<.05; 40.3% in subgroup B; P<.001; and 39.8% in subgroup D; P<.05). The incidence of the composite endpoint was higher in the subgroups with high ischemic and hemorrhagic risks (22.7%) and high ischemic and low-to-moderate hemorrhagic risks (20.9%), compared with 3.6% in subgroup C (P<.05) and 5.7% in subgroup D (P<.001). Among patients with inappropriate treatment, the incidence of the composite endpoint was significantly higher in subgroups with high ischemic and hemorrhagic risks (44.4% vs 7.7%; P=.043) and high ischemic and low-to-moderate hemorrhagic risks (30% vs 14.8%; P=.042)., Conclusions: The prevalence of inappropriate periprocedural/perisurgical treatment was higher in patients with high hemorrhagic risk and low-to-moderate ischemic risk. The incidence of events was higher in patients with high ischemic risk, with inadequate antithrombotic management being associated with a higher event rate in these groups., Competing Interests: CONFLICTS OF INTEREST D. Vivas: speaker's fees from Daiichi Sankyo, AstraZeneca, Bayer, Pfizer, Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, and Ferrer. R. Ferrandis: speaker's fees from LFB, CSL Behring, and Octapharma. M. Anguita: speaker's fees from Eli Lilly & Co, Daiichi Sankyo, AstraZeneca, Bayer, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, and Novartis and consultancy fees from Eli Lilly & Co, Daiichi Sankyo, AstraZeneca, Bayer, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, and Novartis. I. Egocheaga: speaker's fees from Boehringer Ingelheim and AstraZeneca, consultancy fees from AstraZeneca, and support for attending conferences from Novartis. A. Abad-Motos: support for attending conferences from Vifor and Edwards. E. Figuero: speaker's fees from Oral-B, Colgate, Johnson & Johnson, the Spanish Society of Periodontology (SEPA), the Irish Society of Periodontology, the Ukrainian Association of Periodontology, and the French Dental Association of Periodontology; research grants from Dentaid, Lacer, and the University of Bristol; and support for attending conferences from SEPA, the European Federation of Periodontology, the Irish Society of Periodontology, and the French Dental Association of Periodontology. N. Bouzó-Molina: support for attending conferences from MSD. J. Torres: speaker's fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly & Co, Novartis, Pfizer, and Rovi. M.J. Descalzo: speaker's fees from GlaxoSmithKline and support for attending conferences from Daiichi Sankyo. E. Martín-Rioboo: speaker's fees from Servier, Ferrer, and Boehringer Ingelheim. F. Marín: speaker's fees from AstraZeneca and Boehringer Ingelheim; consultancy fees from Boehringer Ingelheim; research grants from AstraZeneca, Ferrer, and BMS; support for attending conferences from Esteve and Novo Nordisk; and participation on advisory boards or data safety monitoring committees for AFNET. The remaining authors declare no conflicts of interest., (Copyright © 2024 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Incidence and clinical impact of inappropriate periprocedural and perioperative management of antiplatelet therapy.
- Author
-
Anguita-Gámez M, Vivas D, Ferrandis R, González-Manzanares R, Anguita M, Esteve-Pastor MA, Echeverri M, Igualada J, Egocheaga I, Nozal-Mateo B, Abad-Motos A, Figuero E, Bouzó-Molina N, Lozano T, Álvarez-Ortega C, Torres J, Descalzo MJ, Catalá JC, Martín-Rioboo E, Molines A, Rodríguez-Contreras R, Carnero-Alcázar M, and Marín F
- Subjects
- Humans, Female, Male, Aged, Prospective Studies, Incidence, Middle Aged, Spain epidemiology, Aged, 80 and over, Inappropriate Prescribing statistics & numerical data, Aspirin therapeutic use, Aspirin adverse effects, Postoperative Complications epidemiology, Platelet Aggregation Inhibitors therapeutic use, Platelet Aggregation Inhibitors adverse effects, Perioperative Care, Thrombosis prevention & control, Thrombosis epidemiology, Thrombosis etiology, Hemorrhage chemically induced, Hemorrhage epidemiology
- Abstract
Background and Aims: There is little evidence on the impact of current recommendations on the use of antiplatelet therapy during the perioperative and periprocedural period in our setting. The aim of this study was to analyze the incidence and clinical impact of inappropriate use of antiplatelet therapy in a population of patients undergoing surgery or a diagnostic or therapeutic procedure in "real life" in Spain., Methods: A prospective multicenter observational study of patients treated with antiplatelet agents requiring intervention was conducted. The incidence of thrombotic and hemorrhagic events at 30 days was analyzed according to peri-intervention management of antiplatelet therapy., Results: We included 643 patients (31.9% women, 39.0% over 75 years of age), most of them (87.7%) receiving aspirin as antiplatelet therapy at a dose of 100mg/day. Indications for antiplatelet therapy were ischemic heart disease (44.9%), cerebrovascular disease (21.7%), and peripheral vascular disease (23.0%). Ischemic risk was low in 74.3%, while 51.6% had a low bleeding risk of the intervention. Periprocedural management was considered appropriate in 61.7% of cases. 30-day incidence of the combined primary endpoint of thrombotic events and major bleeding (12.1% versus 5.0%; p=0.002) and 30-day mortality (5.2% versus 1.5%; p=0.008) were significantly higher in patients with inappropriate periprocedural management of antiplatelet agents., Conclusions: Despite current recommendations for the use of antiplatelet drugs in the perioperative/periprocedural period, their implementation in the "real world" remains low. Inappropriate use is associated with an increased incidence of adverse events, both thrombotic and hemorrhagic., (Copyright © 2024 Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Prospective observational registry of perioperative and periprocedural management of antithrombotic therapy in "real world": the REQXAA study.
- Author
-
Vivas D, Anguita-Gámez M, Ferrandis R, Esteve-Pastor MA, Echeverri M, Igualada J, Anguita M, Egocheaga I, Nozal-Mateo B, Abad-Motos A, Figuero E, Bouzó-Molina N, Lozano T, Álvarez-Ortega C, Torres J, Descalzo MJ, Catalá JC, Martín-Rioboo E, Molines A, Rodríguez-Contreras R, Carnero-Alcázar M, and Marín F
- Subjects
- Humans, Male, Aged, Fibrinolytic Agents therapeutic use, Fibrinolytic Agents adverse effects, Prospective Studies, Hemorrhage chemically induced, Hemorrhage epidemiology, Hemorrhage complications, Risk Factors, Registries, Platelet Aggregation Inhibitors adverse effects, Anticoagulants therapeutic use, Atrial Fibrillation complications, Atrial Fibrillation drug therapy
- Abstract
Introduction and Objectives: There is scarce real-world evidence on the management of perioperative antithrombotic treatment according to current recommendations. The aim of this study was to analyze the management of antithrombotic treatment in patients undergoing surgery or another invasive intervention and to assess the consequences of this management on the occurrence thrombotic or bleeding events., Methods: This prospective, observational, multicenter and multispecialty study analyzed patients receiving antithrombotic therapy who underwent surgery or another invasive intervention. The primary endpoint was defined as the incidence of adverse (thrombotic and/or hemorrhagic) events after 30 days of follow-up with respect to management of perioperative antithrombotic drugs., Results: We included 1266 patients (male: 63.5%; mean age 72.6 years). Nearly half of the patients (48.6%) were under chronic anticoagulation therapy (mainly for atrial fibrillation; CHA
2 DS2 -VASC : 3.7), while 53.3% of the patients were under chronic antiplatelet therapy (mainly for coronary artery disease). Low ischemic and hemorrhagic risk was found in 66.7% and 51.9%, respectively. Antithrombotic therapy management was in line with current recommendations in only 57.3% of the patients. Inappropriate management of antithrombotic therapy was an independent risk factor for both thrombotic and hemorrhagic events., Conclusions: The implementation of recommendations on the perioperative/periprocedural management of antithrombotic therapy in real-world patients is poor. Inappropriate management of antithrombotic treatment is associated with an increase in both thrombotic and hemorrhagic events., (Copyright © 2023 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
30. Cost and burden of poor anticoagulation control with vitamin K antagonists in patients with nonvalvular atrial fibrillation in Spain.
- Author
-
Barrios V, Cinza-Sanjurjo S, Gavín O, Egocheaga I, Burgos-Pol R, Soto J, Polanco C, Suárez J, and Casado MÁ
- Subjects
- Anticoagulants therapeutic use, Blood Coagulation, Humans, Spain epidemiology, Vitamin K, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Stroke epidemiology, Stroke etiology, Stroke prevention & control
- Abstract
Introduction and Objectives: The aim of this analysis was to evaluate the burden and cost of complications due to poor anticoagulation control in patients with nonvalvular atrial fibrillation (NVAF) treated with vitamin K antagonists (VKA) in Spain., Methods: An analytical model was used to estimate annual differences in ischemic stroke, major bleeding, deaths, costs, and potential years of life lost between patients with poor anticoagulation control (time in therapeutic range <65%) and adequate control (time in therapeutic range ≥ 65%) with a 1-year time horizon. Information on the target population (patients ≥ 65 years), event rates, and costs were obtained from national sources. Direct costs in euros (2018) were included from the perspective of the national health system (NHS) and direct and indirect costs from the societal perspective. A sensitivity analysis was performed with post-hoc data from the SPORTIF III/V trials., Results: We analyzed a hypothetical cohort of 594 855 patients, 48.3% with poor anticoagulation control, with an increase of 2321 ischemic strokes, 2236 major bleeding events and 14 463 deaths, and an annual incremental cost between €29 578 306 from the NHS perspective and €75 737 451 from the societal perspective. The annual impact of mortality was 170 502 potential years of life lost. The results of the sensitivity analysis showed that the annual cost would reach €97 787 873 from the societal perspective., Conclusions: Poor anticoagulation control with AVK has a strong impact on loss of health and on increased spending for the NHS., (Copyright © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
31. [Recommendations for clinical practice in diabetes and obesity. The Madrid Agreements. Document agreed by the working groups of the scientific societies: SENDIMAD, SOMAMFYC, SEMG Madrid, SEMERGEN Madrid and RedGDPS].
- Author
-
De Cos AI, Gutiérrez Medina S, Luca B, Galdón A, Simon Chacín J, De Mingo ML, Trifu D, Artola S, Egocheaga I, Soriano T, and Vázquez C
- Subjects
- Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 therapy, Evidence-Based Medicine, Health Education, Humans, Obesity complications, Spain, Diabetes Complications therapy, Diabetes Mellitus therapy, Obesity therapy
- Abstract
The increase in the prevalence of type 2 diabetes and the worldwide expansion of overweight and obesity are intrinsically linked. The percentage of diabetes attributable to weight gain amounts to more than 80% in many countries. This relationship is addressed in a Spanish Consensus Document from SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN and SEMFYC published in 2015 and which gathers best available evidences. Based on the statements of this consensus document, we propose five recommendations for clinical practice to establish a diagnosis of precision and the most appropriate treatment for joint diabetes and obesity. These recommendations have been agreed by the SENDIMAD, SOMAMFYC, SEMG Madrid and RedGDPS Working Groups: 1. For every patient with diabetes and obesity, in addition to the calculation of the body mass index, the percentage of body fat and the approximation to the assessment of body composition should be evaluated throughout the whole process (both at the beginning and follow up). 2. The approximation to the degree and distribution of body fat requires the measurement and recording of the waist circumference of these patients. 3. The integrated assessment of the patient with type 2 diabetes-obesity requires the evaluation of the degree of physical activity and/or characterization of the sedentary condition. 4. The prescription of lifestyle changes should be incorporated into therapeutic education (individualized, flexible, autonomous and sustainable diet and physical activity plan. 5. The pharmacological approach in the treatment of type 2 diabetes-obesity implies the choice of anti-diabetic drugs that facilitate the loss of fat.
- Published
- 2018
- Full Text
- View/download PDF
32. [Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting. The SILVER-AP study].
- Author
-
de la Figuera M, Cinza S, Marín N, Egocheaga I, and Prieto MA
- Subjects
- Administration, Oral, Aged, Antithrombins administration & dosage, Cross-Sectional Studies, Dabigatran administration & dosage, Dabigatran therapeutic use, Female, Humans, Male, Patient Satisfaction statistics & numerical data, Primary Health Care, Rivaroxaban administration & dosage, Rivaroxaban therapeutic use, Stroke etiology, Assessment of Medication Adherence, Antithrombins therapeutic use, Atrial Fibrillation complications, Stroke prevention & control
- Abstract
Objective: To analyse the clinical characteristics and management of patients with non-valvular atrial fibrillation (NVAF) treated with direct oral anticoagulants (DOAC)., Design: Observational, cross-sectional and multicentre study., Location: Autonomous Communities in which the general practitioner can prescribe DOAC (n=9)., Participants: The study included a total of 790 patients on chronic treatment with anticoagulants, and on whom therapy was changed, as well as being currently on treatment with DOAC for at least for 3 months., Main Measures: A record was made of the sociodemographic and clinical management date., Results: Mean age was 78.6±8.4 years, and 50.5% of patients were men. Mean CHADS
2 score was 2.6±1.2, mean CHA2 DS2 -VASc score was 4.3±1.6, and the mean HAS-BLED score was 2.3±1.0. Mean duration of treatment with DOAC was 15.8±12.5 months. Rivaroxaban was the DOAC most frequently prescribed (57.8%), followed by dabigatran (23.7%), and apixaban (18.5%). Of the patients receiving rivaroxaban, 70.2% were taking the dose of 20mg/daily. Of the patients receiving dabigatran, 41.7% were taking the dose of 150mg twice daily, and in the case of apixaban, 56.2% were taking the dose of 5mg twice daily. Satisfaction (ACTS Burdens scale 52.0±7.2 and ACTS Benefits scale 12.1±2.2), and therapeutic adherence (97.8% of patients took their medication regularly) with DOAC were high., Conclusions: Patients treated with DOAC in Spain have a high thromboembolic risk. A significant proportion of patients receive a lower dose of DOAC than that recommended according to their clinical profile. Satisfaction and medication adherence are high., (Copyright © 2017 Elsevier España, S.L.U. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
33. Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.
- Author
-
González-Juanatey JR, Mostaza JM, Lobos JM, Abarca B, Llisterri JL, Baron-Esquivias G, Galve E, Lidón RM, Garcia-Moll FX, Sánchez PL, Suárez C, Millán J, Pallares V, Alemán JJ, and Egocheaga I
- Subjects
- Atorvastatin therapeutic use, Cardiovascular Agents therapeutic use, Drug Combinations, Humans, Ramipril therapeutic use, Salicylic Acid therapeutic use, Atorvastatin administration & dosage, Cardiovascular Agents administration & dosage, Cardiovascular Diseases prevention & control, Medication Adherence, Ramipril administration & dosage, Salicylic Acid administration & dosage, Secondary Prevention methods
- Abstract
Cardiovascular disease is a chronic disorder which is usually already at an advanced stage when the first symptoms develop. The fact that the initial clinical presentation can be lethal or highly incapacitating emphasizes the need for primary and secondary prevention. It is estimated that the ratio of patients with good adherence to secondary prevention of cardiovascular disease is low and also decreases gradually over time. The Polypill for secondary prevention of cardiovascular disease is the first fixed-dose combination therapy of salicylic acid, atorvastatin and ramipril approved in Spain. The purpose of this consensus document was to define and recommend, through the evidence available in the literature and clinical expert opinion, the impact of treatment adherence in the secondary prevention of cardiovascular disease and the use of the Polypill in daily clinical practice as part of a global strategy including adjustments in patient lifestyle. A RAND/UCLA methodology based on scientific evidence, as well as the collective judgment and clinical expertise of an expert panel was used for this assessment. As a result, a final report of recommendations on the impact of the lack of adherence to treatment of secondary prevention of cardiovascular disease and the effect of using a Polypill in adherence of patients was produced. The recommendations included in this document have been addressed to all those specialists, cardiologists, internists and primary care physicians with competence in prescribing and monitoring patients with high and very high cardiovascular risks., (Copyright © 2017 Elsevier España, S.L.U. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
34. Left ventricular geometric patterns after 1 year of antihypertensive treatment.
- Author
-
Luque M, Martell N, Egocheaga I, Fernandez-Pinilla C, Zamorano J, Almeria C, Fernandez-Cruz A, and Ferrario CM
- Subjects
- Adult, Blood Pressure drug effects, Disease Progression, Echocardiography, Female, Follow-Up Studies, Heart Ventricles physiopathology, Humans, Hypertension diagnostic imaging, Hypertension physiopathology, Hypertrophy, Left Ventricular diagnostic imaging, Hypertrophy, Left Ventricular physiopathology, Hypertrophy, Left Ventricular prevention & control, Male, Observer Variation, Ventricular Remodeling drug effects, Ventricular Remodeling physiology, Antihypertensive Agents therapeutic use, Heart Ventricles diagnostic imaging, Hypertension drug therapy
- Abstract
Left ventricular hypertrophy increases the risk for cardiovascular target organ damage, myocardial infarction, and stroke. The authors assessed the patterns of ventricular adaptation in 107 essential hypertensives whose treatment had been withdrawn and its modification after 1 year of hypertension treatment. Blood pressure decreased from 158+/-17/96+/-12 mm Hg to 137+/-15/83+/-10 mm Hg (mean +/- SD; p<0.001); 45% of the patients (49 of 107) had their blood pressure controlled below 140 mm Hg and 90 mm Hg. Although a significant decrease of left ventricular mass index was found in the study, the percentage of patients with normal left ventricular geometry at the completion of the study increased by only 9% (27% to 36%, p>0.05). Left ventricular mass geometry improved in 31% of the patients, remained unaffected in 51%, and worsened in 18%. The data suggest that even while suboptimal antihypertensive treatment reduces left ventricular mass index, either left ventricular hypertrophy or concentric remodeling remains present in a significant number of patients at the end of a 1-year treatment period. The authors conclude that these patients should be considered as a subgroup at high risk and should be treated more aggressively.
- Published
- 2005
- Full Text
- View/download PDF
35. [The usefulness of intravascular echography during the percutaneous dilatation of aortic coarctation].
- Author
-
Goicolea FJ, Macaya C, Iñíguez A, Alfonso F, Hernández Antolín R, Vila i Costa I, Zamorano J, Egocheaga I, and Zarco P
- Subjects
- Aortic Coarctation therapy, Aortography, Cardiac Catheterization, Female, Humans, Middle Aged, Ultrasonography, Aorta, Thoracic diagnostic imaging, Aortic Coarctation diagnostic imaging, Catheterization
- Abstract
An intravascular ultrasound study was performed in a patient, to assess the anatomy of aortic coarctation and the results obtained after percutaneous dilation with a balloon catheter. Intravascular ultrasound imaging provides important additional information, not obtainable with other diagnostic procedures, regarding aortic wall structure and thickness. After balloon dilation, aortic disruption was clearly observed, accounting, together with the stretching of the outer layers of the aortic wall, for the increase in aortic luminal area. Intravascular ultrasound permitted also the accurate assessment of the improvement obtained. Intravascular imaging was clearly superior not only to conventional angiography, but also to transesophageal echocardiography in detecting the mechanism of dilation. We conclude that ultravascular ultrasound, with the additional information that it provides, may help in the selection of patients for percutaneous dilation of the coarctation as well as contributing to the identification of the mechanism of dilation.
- Published
- 1992
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.